Cardiac Device Algorithms for Optimal Outcomes in Patients with Sick Sinus Syndrome by CURRY, JANE,KATHERINE
Durham E-Theses
Cardiac Device Algorithms for Optimal Outcomes in
Patients with Sick Sinus Syndrome
CURRY, JANE,KATHERINE
How to cite:
CURRY, JANE,KATHERINE (2013) Cardiac Device Algorithms for Optimal Outcomes in Patients with
Sick Sinus Syndrome, Durham theses, Durham University. Available at Durham E-Theses Online:
http://etheses.dur.ac.uk/7332/
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or
charge, for personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in Durham E-Theses
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full Durham E-Theses policy for further details.
Academic Support Oﬃce, Durham University, University Oﬃce, Old Elvet, Durham DH1 3HP
e-mail: e-theses.admin@dur.ac.uk Tel: +44 0191 334 6107
http://etheses.dur.ac.uk
2
  
 
Jane Curry, M.B.A. 
Student ID: 000104377 
 
Health Studies 
Graduate School 
 
Cardiac Device Algorithms for Optimal 
Outcomes in Patients with Sick Sinus 
Syndrome 
An evaluation of programming and implanting 
practice in County Durham and Darlington 
Pacemaker Services 
 
 
 
Programme of Study: Master of Science –Research 
 
 
 
 
December 2012 
 Abstract 
Sick sinus syndrome (SSS) is a relatively common chronic condition affecting the 
electrical conduction system of the heart. In the absence of any reversible cause of 
SSS, the most effective treatment is implantation of a permanent pacemaker to 
maintain the heart rate and conduction sequence within the normal physiological 
parameters. Although atrial pacing may be sufficient, in practice most patients in the 
UK receive dual chamber pacing. 
 
There is considerable clinical evidence that long term ventricular pacing can have a 
deleterious effect on the heart function and can increase the risk of heart failure 
hospitalisation, especially in patients with pre-existing cardiac dysfunction. 
A link between the degree of right ventricular pacing (RVP) and the development of 
atrial fibrillation (AF) has also been demonstrated. 
 
Pacemaker manufacturers have therefore developed a variety of programmable 
modes, features and algorithms that can be utilised to reduce unnecessary RVP. These 
include prolongation of atrioventricular delay (AVD), with or without “search”, and 
pacemakers that offer minimal ventricular pacing. Although there are national UK 
guidelines on the use of appropriate pacemaker modes at implant, there is no such 
guidance on appropriate programming strategies. 
 
This research project sought to identify the implanting and programming practice in a 
large pacemaker service in County Durham and Darlington (CD&D) between 2006 
and 2011. The records of 349 patients who were paced for SSS were studied, with a 
follow-up of up to 5 years. Pacemaker implantation practice was compared to national 
audit data. The association between programming strategies and degree of RVP was 
then explored. 
 
The results from this project showed there is a lack of consistency in the historical 
approach to reducing right ventricular pacing by the use of particular devices and 
algorithms. 
Devices with a minimal ventricular pace algorithm reduce the degree of RVP to as 
little as <4% per year, whereas algorithms that altered AVD were significantly less 
effective, reducing RVP to between 17% and 27% per year (years 1-3). The data were 
less robust in years 4 and 5 due to relative small data sizes in each algorithm 
grouping. 
 
There was no observable correlation between algorithm and the amount of AF, but a 
significant correlation was present between the degree of RVP and AF (p<0.05). 
 
Based on these findings, local guidelines for the management of sick sinus syndrome 
have been adapted to recommend minimal ventricular pace devices in patients with 
sick sinus syndrome. 
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Cardiac Device Algorithms for 
Optimal Outcomes in Patients with 
Sick Sinus Syndrome 
Chapter 1 – Introduction to the Research Project 
1.1 Motivation and Background  
Cardiac pacing is an established treatment of symptomatic bradycardia (slow heart 
rate). Technology in this area has developed dramatically, from the fundamentals of 
preventing heart rates dropping below a predetermined rate, to effectively mimicking 
the normal cardiac conduction cycle. 
There has been considerable research into the most effective pacing mode in terms of 
just how it mimics the normal conduction pattern and maintaining that same sequence 
of events (cardiac synchrony), which is closely associated with the mechanical events 
of the cardiac cycle (systole and diastole). 
There is no clear guidance on the programming of these devices in light of emerging 
evidence on the haemodynamic effects of long term ventricular pacing. 
The motivation for undertaking this research was to establish the most effective 
programming strategy in pacemakers that are implanted for one of the main cardiac 
conduction abnormalities – sick sinus syndrome (SSS). Research has highlighted the 
emerging effects of long term ventricular pacing; ensuring that the benefits of 
maintaining stable heart rates is not diminished by the deleterious effects of long term 
ventricular pacing on cardiac function, and utilising some of the technologies to 
reduce the amount of inappropriate pacing. 
 
1.2 Research Environment 
County Durham and Darlington NHS Foundation Trust is a secondary care 
organisation dealing with the acute and community health care needs of a population 
of around 600,000 across County Durham, Darlington, North Yorkshire, Tees Valley 
and South Tyneside.  
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There are two acute hospital sites and a number of community facilities covering a 
large geographical area.  
The two acute hospital sites are Darlington Memorial Hospital (DMH) in the South of 
the County and University Hospital of North Durham (UHND) covering the Northern 
region of the county.  
Bishop Auckland Hospital (BAH) was downgraded from an acute hospital to a 
community facility in 2008 and is positioned approximately mid-way between the two 
acute sites. 
Both of the current acute hospital sites have Cardiac Angiography Units that perform 
coronary angiography and pacemaker implantation. These were both opened in 2004 
with pacemaker implantation starting in 2006. 
Around 250 primary (new) pacemaker implants are carried out per year in these units 
and there around 50 pacemaker replacements per year. 
 
1.3 Research Purpose 
The use of artificial pacemakers via an endocardial approach was introduced in 1958 
by Seymour Furman in the USA.(Hemel and Wall 2008) 
This technology revolutionised the lives of patients with conduction abnormalities 
leading to chronic bradycardias.  SSS is one of the commonest causes of symptomatic 
bradycardias. There has been much debate about the most appropriate choice of 
device or the programmed mode. National and international guidelines on the 
appropriate device prescription for a cardiac rhythm disturbance were published and 
updated most recently in 2008. (Epstein, DiMarco et al. 2008) 
Although there are clear implantation criteria available in these national and 
international guidelines on the type or mode of device implanted for SSS, this does 
not offer guidance on the use of programmable algorithms or specific device features.  
There is considerable research evidence that long term right ventricular pacing (RVP) 
can have a deleterious effect on cardiac function, especially in patients with pre-
existing cardiac functional impairment, the purpose of the research is to evaluate the 
current and historic implanting and programming practice in light of this evidence. 
  5 
 
There is also evidence from the major devices trials that ventricular pacing can 
increase the prevalence of the development of atrial fibrillation. 
This project reviewed data on all devices implanted in the 2 implanting units in 
County Durham and Darlington NHS Foundation Trust (CDDFT with pacemaker 
implantation being undertaken at University Hospital of North Durham and 
Darlington Memorial Hospital) and the devices that have been repatriated from other 
device implant centres that are followed up and programmed at the pacemaker clinics 
in CDDFT. 
The research sought to evaluate the programming rationale in light of the degree of 
right ventricular pacing per year and the percentage burden of atrial fibrillation per 
year for patients with a primary implant reason of SSS. 
It is anticipated that this will offer an evidence base for the most effective strategy for 
device prescription and programming in this patient population, and hence lead to 
departmental protocols to ensure patients receive the most appropriate device and the 
most effective programming regime. 
 
1.4 Research Outline 
SSS refers to an impairment of the automaticity of the sinus node, also known as sinus 
node dysfunction. The sinus node initiates an impulse which is then propagated across 
the atria and down the ventricles thus enabling the mechanical events that cause 
cardiac contraction and relaxation. The cause is often conduction tissue fibrosis but 
can be post-surgical or drug induced (Bennett 2006 p. 154). 
Implantation of a pacemaker is the treatment of choice in patients with symptomatic 
SSS without a reversible cause. 
 
The normal intrinsic cardiac conduction starts within a dense collection of pacemaker 
cells which initiate impulses and spontaneous electrical activity – this area is known 
as the sinoatrial node and is located in the right atrium at the junction of the superior 
vena cava (Ellenbogen and Wood 2008 p: 1). SSS is the term used to describe a 
failure of this area of specialised cells automaticity, regularity, rate or a combination 
of aetiologies. 
  6 
 
Pacemakers seek to mimic part or all of the electrical conduction system of the heart 
ensuring activation of the mechanical events of normal atrial and ventricular systole 
and diastole. Chapter 2 provides a clinical overview of the electrical cardiac 
conduction system and some of the major conduction abnormalities that would 
warrant permanent pacing. Chapter 3 gives a basic overview of pacemaker 
components and function. 
Physiological or atrial based pacing is the mode of recommendation for patients with 
a primary indication of SSS.  
In pure SSS a single chamber atrial pacemaker provides right atrial pacing; the right 
atrium is the chamber from which sensing takes place and the mode of operation is 
inhibition of artificial stimulus upon a sensed event – this mode of device is called 
AAI (Fig.4.2.1).  This type of device is indicated “in the management of sick sinus 
syndrome in patients in whom, after full evaluation, there is no evidence of impaired 
atrioventricular conduction; in this situation, single-chamber atrial pacing is 
appropriate” (National Institute for Clinical Excellence 2005) 
The rationale here is that the electrical disturbance is isolated to the sinus node only 
and that normal conduction takes place beyond this point. The statement “after full 
evaluation” requires an assessment of the likelihood of failure of normal 
atrioventricular conduction to be undertaken. However there are no absolute 
predictors of future development of atrioventricular block (AVB) with time, given 
that a pacemaker lasts 7-10 years until battery depletion. 
In clinical practice, patients with SSS rarely receive a single chamber atrial pacemaker 
in favour of a dual chamber device which has the ability to both sense and pace the 
right atrium and the right ventricle in a synchronous way. If we consider the UK 
national implanting practice it is clear that single chamber atrial pacing is rare, 
accounting for less than 1% of all new pacemaker implants (Cunningham  2009) . 
Chapter 4 deals with the local and national context for device prescriptions and 
implanting behaviours 
Clinical practice in the UK is to avoid the use of single chamber atrial pacemakers in 
patients with SSS as the primary mode of choice, despite National Institute for 
Clinical Excellence (NICE) recommendations.  
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The rationale for the deviance from recommended practice is the potential for the 
development of AVB in patients with SSS, which would require further premature 
intervention to upgrade the system to dual chamber. Research undertaken in Denmark 
comparing single chamber atrial pacing to single chamber ventricular pacing 
suggested “The main argument for using DDD pacing is the concern, that the patients 
will develop symptomatic atrioventricular (AV) block. In the Danish AAI/VVI trial, the 
risk of AV block was approximately 0.6% per year” (DANPACE 2009). 
In a prospective study looking at patients with a pacemaker indication of SSS, 225 
consecutive patients with a primary pacemaker indication of SSS were randomised to 
either single chamber atrial paced devices or single chamber ventricular paced 
devices. Of the 110 patients in the pure atrial paced device cohort, four went on to 
develop grade 2 or grade 3 atrioventricular block. This would represent, in this small 
sample, a 4% incidence of atrioventricular block overall with an annual incidence of 
0.6% per year (also noted in the DANPACE study). (Andersen, Nielsen et al. 1998) 
It is also well established that ventricular pacing has a deleterious effect on cardiac 
function; right ventricular pacing has the effect of inducing an abnormal cardiac 
activation sequence resulting in left bundle branch block (LBBB) which can cause a 
degree of left ventricular remodelling. Le Clercq et al reported this remodelling as 
thinning of the areas of myocardium which were activated earlier than normal and a 
characteristic thickening of the areas which were activated later than normal. The 
clinical picture of such patients is one of reduced systolic function, increased hospital 
admissions, worsening of CHF and increased incidence of AF (Leclercq, Gras et al. 
1995) .  Further analysis of research data relating to the effects of long term RV 
pacing is provided in Chapter 5. 
The National Pacemaker and ICD (implantable cardiac defibrillator) Database 
managed by Central Cardiac Audit Database (CCAD) (Cunningham 2009), shows that 
the majority of devices implanted in the UK in 2009 are dual chamber devices  with 
or without rate responsive functionality. SSS is also shown to be the commonest 
primary indication for pacemaker implantation running at 27%, yet it is a 
contradiction that less than 1% of patients receive a pure single chamber atrial based 
pacemaker. 
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There have been multiple randomised clinical trials examining the various prescribed 
pacemaker modes and their outcomes in terms of mortality, quality of life, incidence 
of atrial fibrillation and stroke. A review of the major clinical trial is detailed in 
Chapter 6. 
There are more recent devices on the market that effectively operate as single 
chamber atrial based pacemaker systems but with a back-up mode of dual chamber 
atrioventricular synchronous pacing – they are classed as minimal ventricular pacing 
devices. These devices function in such a way as to promote intrinsic atrioventricular 
(AV) conduction whilst only reverting to dual chamber synchronous pacing in the 
presence of confirmed AV block (Milasinovic1, Tscheliessnigg et al. 2008; Medtronic 
Incorporated 2010; Sorin Group 2012). However the recent implanting information 
from CCAD (more recently taken over by the National Institute for Cardiovascular 
Outcomes and Research) describes a less than 0.5% rate for these devices. This may 
in part be explained by the cost of these devices, or implanting centres may use dual 
chamber synchronous devices and programme the atrioventricular delay longer than is 
physiological in order to promote normal AV conduction. Another explanation may 
be miscoding of the device into CCAD.  
In Chapter 7 an appraisal of the programming strategies available to reduce RVP was 
undertaken along with analysis of existing evidence of the efficacy of these pacing 
strategies. 
The practice within the pacemaker services in CDDFT is to implant a mixture of dual 
chamber synchronous pacemakers and minimal ventricular pacing devices for patients 
with an indication of SSS. Current practice is somewhat ad hoc with a mixture of dual 
chamber devices with atrioventricular delay ‘programmed long’, and /or the addition 
of a ‘search algorithm’ which automatically extend the atrioventricular delay to 
encourage normal conduction, or minimal ventricular pace devices.   
The rationale of extending AV delay relates to the period of time the atrial impulse is 
delayed before conduction down to the ventricles, the physiological importance of this 
is to allow optimal ventricular filling prior to systole. Artificially extending this delay 
can be non-physiological. The physiological effects of these algorithms needs further 
review and this is also included in Chapter 7. 
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1.5 Ethics Considerations 
Ethical approval has been received from both the host NHS organisation sponsoring 
the research and the academic institution overseeing the project. 
A full summary of the research proposal and protocol was also submitted to County 
Durham and Darlington NHS Foundation Trust Research Department, which 
recommended a full submission via the Integrated Research Application System. The 
research project was approved on 18
th
 October 2011 by the Research Review Board 
Chair of County Durham and Darlington NHS Foundation Trust. (Appendix 1) 
As part of the standard requirement for those undertaking research projects the author 
attended and completed a course entitled an Introduction to Good Clinical Practice 
(GCP) – A practical guide to ethical and scientific quality standards in clinical 
research, presented by National Institute for Health Research on 31
st
 August 2011. 
(Appendix 2). 
A full summary of the research proposal and protocol was submitted to Durham 
University for ethical consideration in June 2011. As this project does not require the 
enrolment of participants it did not therefore require a full committee review by the 
School of Medicine and Health Ethics Sub-Committee. Ethical approval was granted 
by Chair’s action on 30th June 2011. (Appendix 3) 
1.6 Research Methodologies 
 The author of this thesis has in excess of 20 years clinical experience of 
implantable cardiac device management and completed both nationally (Heart 
Rhythm UK) and internationally (International Board of Heart Rhythm 
Examinations) accredited cardiac device specialist examinations. Much of that 
technical and clinical knowledge has been applied to the development of this 
project. 
 Review of current literature related to device prescription, inspecting national 
and international recommendations and the clinical evidence base. 
 Review of research into the effect of ventricular pacing on cardiac function, 
incidence of arrhythmias, related hospitalisations and quality of life. 
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 Review of the research data and randomised clinical trials detailing outcomes 
in patients with differing pacing modes. 
 Appraisal of the pacemaker algorithms of the companies providing devices for 
ventricular pace avoidance including minimal ventricular pacing, MVP™, 
SafeR™ and AV delay search algorithms. 
 An audit of all pacemakers implanted in CDDFT since the service commenced 
in June 2006, covering a period to June 2011 (5 years), and all repatriated 
patients from other implanting centres. This audit shows how the local 
implanting services mirror the national picture in-line with the CCAD reports. 
The percentage of patients implanted with a primary indication of SSS, and the 
types and modes of devices implanted was identified. The data further shows 
the efficacy of the differing algorithms for ventricular pace avoidance to 
identify the optimal clinical outcome in terms incidence of atrial fibrillation 
and the overall percentage of ventricular pacing. 
1.7 Research Objectives 
Identify the demographical data on the pacemaker population in County Durham and 
Darlington. In this population, further identify the primary indication for pacing and 
specifically the percentages of patients with SSS and the development of AV block. 
Detail the historical use of single chamber atrial base pacemaker systems, the use of 
dual chamber devices and minimal ventricular pace devices. 
Appraise the existing evidence to support a ventricular pace avoidance strategy. 
 Identify evidence to support a particular implanting and programming strategy over 
another. Identify the mode of device and programming strategy that is most effective 
in producing a statistically significant reduction in RVP pacing whilst protecting AV 
conduction. 
Obtain evidence from the pacemaker data review on any effect of differing mode 
strategies or algorithm programming on percentage of RV pacing and burden of atrial 
fibrillation. 
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Use data analyses to identify clinically significant differences in terms of the 
percentage of RV pacing of the differing algorithms, and identify the overall atrial 
fibrillation durations and correlate with the amount of RV pacing. 
Based on the evidence, what is the most effective programming strategy in patients 
with SSS in terms of reduced inappropriate right ventricular pacing, and is there a 
correlation between this reduced right ventricular pacing and the incidence of atrial 
fibrillation? 
1.8 Planned Project Time-Lines 
The planned project time-lines were generally reached on schedule, as indicated 
below. 
Literature review covering Chapters 1-7 including refinement of the research question 
took approximately 6 months from February – August 2011. 
The systematic review/audit of all pacemaker implants commenced from August  
2011 onwards. Data collection was be expected to last 3 months and included all 3 
follow-up centres in County Durham and Darlington. The sample size was expected to 
be around 1500 patient records, around 400 (27% expected rate of SSS nationally 
from CCAD national data) likely to be patients with an indication of SSS.  
The data analysis phase commenced with the development of datasets, and analysis of 
the data sources that added evidence to the research question. Statistical analyses and 
training in the use of the statistical software (Statistical Packages for the Social 
Sciences –SPSS 19) and data interpretation was expected to take up to 4 months. 
The remainder of the final year dealt with the writing up of the thesis beyond the 
literature review to include data analysis and validation, assessing data against the 
research questions, development of conclusions and discussions based upon the 
evidence, appraisal of the evidence and identification of any weaknesses in the 
methodology and conclusions drawn 
 
 
  12 
 
Chapter 2 – The Cardiac Electrical Conduction System 
2.1. Anatomy of the Cardiac Conduction System 
The American College of Cardiology (ACC), American Heart Association (AHA) and  
Heart Rhythm Society (HRS) updated guidelines “Device Based Therapy of Cardiac 
Rhythm Abnormalities”(Epstein, DiMarco et al) in 2008. This document developed 
clinical decision making tools based on the patients presenting symptoms and rhythm 
abnormalities. 
Patients’ symptoms and rhythms were stratified into classes for the two main cardiac 
conduction abnormalities, sinus node dysfunction and atrioventricular node 
dysfunction. 
 To understand the principles and concepts of cardiac pacing, a review of these 
electrical disturbances in relation to the anatomical sites of these abnormalities and 
the cardiac conduction pathways is essential. (Ellenbogen and Wood 2002 pp 1).
 
Fig 2.1.1. Electrical conduction system of the heart 
(http://en.wikipedia.org/wiki/Electrical_conduction_system_of_the_heart)  *permission granted under 
creative commons attribution. 
 
1. Sinoatrial node (SAN): This is an area of specialised cells located at the 
junction of the right atrium and the superior vena cava. It has a rich blood 
supply and abundance of autonomic innervation. This area of specialised cells 
1. Sino-atrial node 
2. Atrioventricular node 
3. Bundle of His 
4. Left Bundle Branch 
5. Left posterior Fascicle 
6. Left Anterior Fascicle 
7. Left ventricle 
8. Ventricular Septum 
9. Right Ventricle 
10. Right Bundle branch 
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is sometimes referred to as the “natural cardiac pacemaker” - the normal 
resting rate of the SAN depolarisation or impulse initiation is 60-100 beats per 
minute (bpm). 
2. Atrioventricular node (AVN): This forms the electrical bridge between the 
atria and the ventricles situated within the interatrial septum. The AVN, like 
the sinoatrial node, is an area of highly innervated cells with a rich blood 
supply. 
Having received impulses from the SAN, the AVN delivers impulses to the 
Bundles of His. If the AVN fails to receive an impulse from the SAN, in the 
case of some forms of sinus node dysfunction or SSS, the AVN can initiate 
impulses in isolation of receipt of stimuli at a rate of 40-60 bpm. This allows 
for maintenance of cardiac conduction in the presence of failure of the SAN, 
rather like a back-up electrical generator but at a slower rate. 
3. Bundle of His: Purkinje fibres, made up of specialised cardiac muscle cells, 
emerge from the distal area of the AV node to form the His bundle. Unlike the 
SA and AV nodes, the His bundle is less innervated although it still has a rich 
blood supply.  
4. Bundle branches: an extremely complex network of interlacing Purkinje fibres 
make up the bundle branches. The branches form “electrical roads” into the 
myocardium of the ventricles with the left ventricle supplied by two branches; 
anterior and posterior fascicles, and the right ventricle with a single branch. 
The bundle branches are a source of rapid electrical conduction causing almost 
simultaneous ventricular activation. (Ellenbogen and Wood 2008 pp:1-4) 
 
The electrical impulse arises in the SAN situated in the right atrium. This impulse is 
then propagated to the left atrium and to the AVN where it is held for a brief period of 
time (100-200ms) before travelling down the Bundle of His to the branches supplying 
the left and right ventricles. This electrical circuit stimulates the mechanical events of 
atrial and then ventricular depolarisation and systole. (Rogers 1999; Ellenbogen and 
Wood 2008 p.46) 
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2.2. Electrical Sequence Related to the Electrocardiogram 
The electrocardiogram is a graphical representation of the electrical signals produced 
by the heart during a single cardiac cycle. 
This signal can be detected from the body surface using electrodes attached to an 
electrocardiogram recorder or monitor.(Julian, Cowan et al. 1998 p: 11) 
The initial electrical deflection is the P wave and this represents the spread of 
electrical activation through the atria.  (Topol and Califf 1998 p: 1550) 
The PR interval represents the time taken for the impulse to propagate over the atria, 
AV node and His bundle. 
The QRS complex represents the spread of depolarisation through both ventricles. 
Finally the T wave represents ventricular repolarisation. (Julian, Cowan et al. 1998 
p:14) 
 
 
Fig 2.2.1 Electrocardiagram Components 
http://en.wikipedia.org/w/index.php?title=File:SinusRhythmLabels.svg&page=1, 
(with permission) 
 
 
2.3. Electrical Mechanical Sequence 
The electrical sequence is the precursor to the mechanical events that allow the heart 
to contract and relax (National Heart Lung and Blood Institute 2011) 
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Atrial depolarisation starts from the SAN and conducts radially through the atria 
taking about 0.1 seconds. This spread of electrical activity forms the P wave on the 
surface ECG and causes atrial contraction, pushing blood into the lower pressure 
ventricular chambers. 
Conduction in the AV node is slower, allowing for optimal ventricular filling; as the 
atria begin to relax, a spread of electrical depolarisation from the His Bundle at the 
top of the ventricular septum spreads rapidly down the bundle branches to the 
Purkinje fibres and all parts of the ventricles  in approximately 0.08 -0.1 seconds. This 
spread of electrical activity forms the QRS complex on the surface ECG and causes 
ventricular contraction (systole). 
The final part of the electrical cycle is repolarisation of the cardiac cells 
corresponding to ventricular relaxation (diastole) and the T wave deflection on the 
surface ECG.(Barret, K.E. 2010) 
2.4. Cardiac Conduction Abnormalities 
Sinus node dysfunction relates to a malfunction of the SAN. This can result in failure 
to initiate an impulse, intermittently or persistently, or at a rate slower than 
physiologically appropriate. This can manifest as sinus bradycardia, sino-atrial block, 
sinus arrest and bradycardia-tachycardia syndrome (atrial flutter, fibrillation and 
paroxysmal atrial tachycardias).  
In the absence of a preceding impulse from the sinus node, the cardiac conduction 
system has a “back-up” electrical escape function which is initiated by specialised 
tissue located in the atrioventricular node, allowing for continuation of ventricular 
depolarisation and consequential ventricular systole. This rhythm it at a slower rate, 
typically around 40-50 beats per minute and lacks any chronotropic regulation 
(autonomic heart rate control).(Camm and Fei 1996; Bennett 2006 pp:16-18) 
SSS is an umbrella term used to describe all the rhythm abnormalities detailed that 
manifest themselves as a result of a failure or malfunction of the SAN. As a result of 
this syndrome there are a large variety of symptoms from vague headaches, 
palpitations and chest pains to blackouts, dizziness and nausea. 
 
Atrioventricular block describes an impairment of the signal between the atria and the 
ventricles and comprise 3 types: 
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First degree AV block – delay in the impulse travelling from the atria to the ventricles 
in excess of 200ms. 
Second degree AV block – gradual lengthening delay in the impulse between the atria 
and the ventricles until one of the impulses is blocked (Mobitz type I). Further 
development of AV block results in every alternate atrial impulse being conducted to 
the ventricles – a 2:1 association of atrial impulses to every ventricular response 
(Mobitz type II) 
Third degree AV block – no association between the electrical impulses of the atria 
(SA node) and the ventricular conduction, hence the ventricular escape “back-up” 
conduction circuit produces ventricular depolarisation. (Bennett 2006 pp: 141-146) 
 
2.5. Indications for Cardiac Pacing 
The implantation of a permanent cardiac pacemaker is an important decision and 
should be based on solid clinical evidence.  
This is an operative procedure involving the placement of electrodes and leads into 
the heart. Once placed the reversal of this lead placement or removal attract 
significant clinical risks (further discussion on implant process in Section 3.4). 
The American Heart Association (AHA) in joint consultation with the American 
College of Cardiology (ACC) first developed implantation criteria in 1984 which was 
most recently updated in 2008 (Epstein, DiMarco et al 2008). 
These guidelines must be seen in the context of the patients’ presentation and the ever 
evolving technological and clinical science advancement (see Section 4.1 Prescription 
guidelines).  
The AHA and ACC developed a classification matrix depending on the clinical 
presentation, symptoms, type of rhythm disturbance and the clinical evidence base. 
Permanent pacemaker implantation is undertaken in the absence of any reversible 
cause of the bradycardia.  
 
2.5.1. Temporary Cardiac Pacing 
Temporary pacing therapy is used when the bradycardia is considered secondary to an 
acute event: commonly this would be an acute myocardial infarction. This involves 
either a temporary or permanent impairment to the conduction system due to ischemia 
of the SAN tissues or AVN tissue following coronary artery occlusion. This may 
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reverse with reperfusion and should be monitored after the acute event to assess if 
normal SAN or AVN activity resumes. 
Other potential reversible causes of bradyarrhythmias includes neurological deficits 
affecting the carotid sinus which regulates the brains control of heart rate, some 
infections which can cause transient bradyarrhythmias such as Lymes disease, 
endocarditis or myocarditis and certain medications can cause or precipitate cardiac 
conduction problems.(Ellenbogen and Wood 2002 pp: 41) 
Temporary cardiac pacing can be external or intracardiac. External pacing or 
transcutaneous pacing, uses large electrodes placed on the patients’ chest delivering 
around 0.1 Joules of energy to the chest surface – although not necessarily painful, 
prolonged external pacing can become uncomfortable. 
Intracardiac temporary pacing requires the placement of an electrode to either the 
epicardial or endocardial heart muscle surface in much the same way as permanent 
cardiac pacing (see Section 3.4), this electrode is attached via an electrical conducting 
lead to an external, battery operated pulse generator capable of delivering varying 
electrical outputs depending on the degree of energy required to pace the heart and at 
varying rates depending on the levels of support the heart requires. 
 
2.5.2. Permanent Cardiac Pacing 
A permanent pacemaker has leads with electrodes placed into the heart with the pulse 
generator inserted in the subcutaneous tissue of the upper left or right chest, in the 
pre-pectoral region for adults. 
The implantation of a permanent pacemaker system has a strong and well established 
evidence base in terms of its efficacy (Vardas, Auricchio et al. 2007) and in absence 
of any reversible cause it remains the treatment of choice in symptomatic 
bradyarrhythmias. (Pacemaker implantation Section 3.4) 
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Chapter 3 – The Cardiac Pacemaker 
3.1. Cardiac Pacing Concepts 
The first totally implantable pacing system was utilised by Senning in 1958: since 
then the use of pacemakers has seen a rapid clinical and technological evolution. 
(Topol and Califf 1998)  
The fundamental effect of cardiac pacing is to promote and maintain, as near as 
possible, the normal electrical conduction of the intrinsic cardiac electrical circuit. 
This is achieved by the placement of electrodes, generally inside the heart, that can 
stimulate the cardiac tissue. 
These electrodes are connected by leads to a small pulse generator which is placed 
under the subcutaneous tissue of the chest wall. The pulse generator delivers electrical 
stimuli via the leads to the heart at appropriate intervals, such that it mimics the 
normal intrinsic electrical sequence. 
The artificial stimulus causes depolarisation of the excitable cardiac tissues at the 
interface of the electrode. Commonly there is an electrode in the right atrium and 
another in the right ventricle. In dual chamber synchronous pacing the atrial artificial 
stimulus causes atrial depolarisation, there then follows a brief delay of around 150-
200ms, mimicking the time taken for the impulse to spread across the atria and reach 
the AV node. This period of time is followed by an artificial ventricular stimulus 
which causes ventricular depolarisation. (Ellenbogen and Wood 2002 pp: 299-303;  
Ellenbogen and Wood 2008 p: 299) 
 
 
Fig 3.1.1 ECG Representation of Synchronous Atrioventricular Pacing 
AP=atrial pace, VP= ventricular pace. Red arrow=pacing rate, blue arrow=AV delay. 
 (Medtronic Inc. CorePace (2008) educational multimedia power point presentations-permission 
granted). 
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The electrical representation of pacing can be seen above. AP causes a sharp upward 
deflection which is the electrical stimulus from the pacemaker, producing atrial 
depolarisation which is represented by the P wave. The blue arrow shows the brief 
timing delay (AV delay) programmed into the pacemaker allowing for the 
depolarisation to spread across the atria to the AV node and His Bundle (PR interval 
in the normal intrinsic cardiac conduction), before the second sharp deflection from 
the pacemaker stimulus, VP, causing depolarisation of the ventricles. The overall 
timing, shown by the red arrow, dictates the heart rate, the time from AP to AP. This 
is nominally programmed at 60 pacemaker pulses per minutes to mimic the general 
resting heart rate of 60 beats per minute. 
 
Fig. 3.1.1 represents the fundamental concept of atrioventricular synchronous pacing: 
further discussion follows detailing how and when the pacemaker operates. 
 
3.2. Cardiac Pacemaker Function 
A modern day cardiac pacemaker has a number of discrete operating functions: 
 The ability to stimulate myocardium such that “an artificial pacing stimulus 
excites cardiac tissue by the creation of an electrical field at the interface of 
the stimulating electrode and the underlying myocardium” (Ellenbogen and 
Wood 2008 p: 46) 
  Pacing: This electrical stimulus causes action potentials propagating away 
from the site of the stimulus. The source of this electrical stimulus is the 
power source in the pacemaker and the delivery of this stimulus is via a 
conduction lead to the point of delivery at the tissue electrode interface of the 
myocardium. 
 Sensing: This same electrode/myocardium interface needs to be able to detect 
native intra-cardiac electrical signals in order to prevent the delivery of an 
artificial stimulus.  
 Timing: A timing circuit comprises a series of “clocks” that operate 
depending on the input (sensed intrinsic cardiac signal) and output circuitry 
(pacing- artificial electrical stimulus). The device also has timing intervals for 
refractory periods, blanking periods and atrioventricular delays. These periods 
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allow for the requirements of repolarisation at a cellular level and the 
physiological requirements of mechanical cardiac actions.  
There are also rate limiting circuits to deliver pacing stimuli up to a maximum 
rate and a safety mechanism to prevent pacemaker “runaway”, an effect that 
can allow pacemakers to follow apparent intrinsic sensed events at higher 
than physiological rates.  
These timings essentially mimic the physiological delays in the electrical 
conduction pathways that allow for atrial filling, atrial systole, ventricular 
filling and ventricular systole. Blanking periods mimic refractory periods 
allowing for the cardiac cells to repolarise. 
 
3.2.1. Pacemaker Components 
 Communication: Telemetry coil – this allows for interrogation of the device 
via an external programmer. It can also allow for external interaction with the 
device such as reprogramming features – rate, intervals and algorithms. The 
device has a degree of storage memory allowing for rhythm information with 
intracardiac ECG’s to be stored for scrutiny by clinicians. 
 Power source:  a lithium iodine chemical battery to power the internal 
electrical components and the cardiac stimulation.  
 Rate adaptive sensors: the sinus node augments the heart rate in response to 
biological need and under the influence of the autonomic nervous system 
(chronotropic response). In the presence of impaired sinus node function this 
augmentation of heart rate is disturbed. Much of the need for heart rate 
response is initiated by exercise or exertion. Within pacemakers small sensors 
are built in -these detect movement or vibration and increase the pacing rate 
accordingly. There are other more physiological sensors that detect breathing 
rate and can blend with movement sensors to provide more sensitive rate 
augmentation. This function is known as rate response and often denoted by 
the letter R after the pacing mode, e.g. DDDR. 
(Camm and Fei 1996; Ellenbogen and Wood 2008 pp:102-109) 
 
  21 
 
 
Fig 3.2.1 – Permanent Pacemaker (scale is approximately 110% of actual) 
Medtronic, Inc- CorePace training slides with permission (May 2011)  
 
3.3. Pacemaker leads 
The pacemaker leads generally have a greater clinical longevity than the pacemaker. 
On average the pacemaker battery life is 7-10 years. The battery is within the 
pacemaker which is a hermetically sealed system, the whole pacemaker is replaced as 
the battery starts to deplete. 
This involves removing the electrical pin end of the pacemaker lead(s) from the 
pacemaker via small grub screws which fix the leads into the header of the pacemaker 
completing the electrical circuit. 
The leads remain in the heart, with a new pacemaker attached with a further 7-10 year 
battery life expectancy. 
The leads inside the heart become fibrosed within the muscle tissue of the heart, this 
makes it not only very difficult to remove leads but potentially dangerous with a 0.8% 
risk of death and 1.9% risk of major complication (Ellenbogen and Wood 2008 
pp:265)  
Due to the generally elderly population of pacemaker patients, the original leads are 
expected to last the existing lifetime of the patients, however pacemaker implants in 
the younger patient carry a significant increase in the likelihood of requiring new 
leads at some point in their pacemaker management; 
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Pacemaker leads have the following components: 
 The electrode: this is the distal part of the lead that is in contact with the 
cardiac tissue. The fixing method of the electrode to the cardiac tissue may 
take a number of different forms such as silicone tines which passively anchor 
to the cardiac muscle / atrial tissue or small retractable screws which actively 
fix the electrode to the cardiac tissue. The interface of the electrode at the 
tissue is important in ensuring as small a current density is ensured over a 
large surface area. This can be achieved with porous tips with edges and ridges 
of high current density. 
 The conductor: this refers to the wires inside the lead that connect the 
pacemaker, sited just below the clavicle, to the electrode in the heart, allowing 
the conduction of electrical stimuli produced in the pacemaker to the cardiac 
tissue. The conductor is made up of a nickel alloy (good conducting properties 
and less prone to corrosion) formed in multiple strands coiled along the length 
of the wire. In a unipolar lead this is a single coil conductor, in a bipolar lead 
this is a dual coil conductor. The characteristics of the conductor must allow 
for flexing and movement at a rate of 60-70 beats per minute minimum for the 
lifetime of the lead (on average 15-25 years). 
 Insulation: this is the material covering the conductor coils from the point of 
insertion into the pacemaker through to the electrode at the cardiac muscle 
interface. The material used as the insulator can be either silicone or 
polyurethane: more recent lead designs use a blend of both materials. The 
insulator protects the conductor and ensures no current drain into the 
surrounding tissues. 
 Connectors: these are the pins that insert into the head of the pacemaker 
completing the electrical circuit. These are now standard lead connectors such 
that one manufacturer’s leads will fit into another manufacturer’s pacemaker. 
(Ellenbogen and Wood 2008 pp:78-96)  
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Fig 3.3.1 Permanent pacemaker and Passive Fixation Lead – black rounded tip at end of lead is 
the electrode, small thin tines above the electrode are the fixing mechanism anchoring 
the electrode to the trabeculae of the heart muscle. Coils can be seen of the conductor 
and this is covered by a see-through silicone insulator. The circuit is completed by the 
electrical pin which fits into the header, which is also see through, at the top of the 
pacemaker. There is a small circle of silicone at the distal pin in the header – this is 
the point of insertion for a small screw-driver to fix the connector pin in place. 
  http://en.wikipedia.org/wiki/File:St_Jude_Medical_pacemaker_with_ruler.jpg (with 
permission) 
 
3.4. Pacemaker Implantation 
The implantation procedure is undertaken in either an operating theatre or more 
commonly in a cardiac angiography unit, with sufficient air changes required for a 
sterile procedure. 
  24 
 
There must be either a fixed or mobile image intensifier (x-ray machine) as the lead 
insertion and placement must be performed under fluoroscopy. 
The patients’ electrocardiogram (ECG) must be monitored to confirm that the 
artificial electrical stimulus is capturing the heart tissue and resulting in a paced 
rhythm on the surface ECG. 
The procedure is carried out by an implanting physician, generally a consultant 
cardiologist or specialist registrar in cardiology, under sterile conditions. 
The pre-pectoral region of the chest wall is prepared (below the collar bone), usually 
on the left hand side unless the patient is left handed. A local anaesthetic is 
administered; general anaesthesia is not usually indicated in adults for first implants. 
An incision in the area of the subclavian or more superiorly the cephalic vein is made, 
and either a direct cut-down to the vein or a needle is used to access the vein 
(Seldinger technique) (Chiariello 1978). 
The pacemaker lead is inserted into the vein and visually guided, with the aid of 
fluoroscopy, to the right atrium via the superior vena cava. 
If two leads are to be inserted, the ventricular lead is often inserted first via the 
tricuspid valve between the right atrium and the right ventricle and generally placed 
into the apex of the right ventricle. 
 
 
Fig 3.4.1 Implantation of Permanent Pacemaker  
(www.understandingatrialfibrillation.com) *permission sought 2011 and 2012 – site unobtainable. 
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The atrial lead is then inserted via the subclavian or cephalic vein and visually guided 
into the right atrium where it is placed into the right atrial appendage (a small 
redundant fold in the RA). Due to the lack of dense muscle or trabeculation to 
passively anchor the lead in the atrium, operators tend to prefer an active screw 
mechanism that is deployed out of the distal electrode of the lead. 
 
A pocket is manually separated in the pre-pectoral region between the muscle and the 
sub-cutaneous tissue to house the pacemaker. The leads are then tested to assess the 
size of the signal detected via the leads and the degree of energy required in order to 
stimulate the heart muscle. 
 Sensing test: this test assesses the size of the signal from electrode at the end 
of the lead. This is called the intra-cardiac signal, and it relates to the intrinsic 
cardiac stimulus that is detected at the electrode interface. This signal is 
important; all pacemakers respond to the detection of an intrinsic signal by 
inhibiting the need for an artificial stimulus from the pacemaker.  
The optimal ventricular signal should be 3-30 millivolts at implant, and the 
atrial signal 1-6millivolts (Ellenbogen and Wood 2008 pp:70)  
 Stimulation threshold test: “cardiac pacing involves the delivery of a 
polarizing electrical impulse from an electrode in contact with the 
myocardium with the generation of an electrical field of sufficient intensity to 
induce a propagating wave of cardiac action potentials” (Winfree 1990).  
This statement from A.T.Winfree offers the fundamental principles of cardiac 
artificial stimulation and the importance of the stimulation threshold test. At 
implant, the clinical team needs to assess the minimal amount of energy 
required to initiate the propagation of the electrical wave of action potential 
that will precede the mechanical event of systole. This needs to be sufficient to 
initiate the action potential but not so large as to drain the battery of the device 
shortly after implant. Ideally, this is <1.0 volt over a fixed pulse duration of 
0.5milliseconds. (Ellenbogen and Wood 2008 p:49) 
 
Once satisfactory electrical parameters are confirmed, the leads are sutured above the 
venous entry to the chest muscle, the connector pins are inserted into the pacemaker 
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header and screwed into contact, and the pacemaker is placed into the pocket in the 
pre-pectoral region of the chest. The wound is then sutured and dressed. 
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Chapter 4 – Pacemaker Prescription 
4.1. Prescription Guidelines 
As previously described ACC/AHA/HRS updated ‘The Guidelines for Device Based 
Cardiac Rhythm Abnormalities’ in 2008. The decision to pace is based on the 
evidence base and ranking depending on that weight of evidence such that data 
derived from multiple randomised control trials involving large numbers of 
individuals is ranked at Level A. Data derived from a limited number of trials and 
comparatively small number of patients or from observational data was ranked a 
Level B, Level C was designated for evidence based on consensus of experts being 
the primary source of evidence. (Epstein, DiMarco et al. 2008)  
Furthermore the indication for cardiac device therapy was classified depending on a 
benefit versus risk ratio. 
Symptomatic bradycardia refers to a documented bradyarrhythmia that has a direct 
correlation to symptoms such as transient dizzy spells, syncope or pre-syncope. 
There are International Guidelines “A Report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines”(Epstein, 
DiMarco et al. 2008) that give classifications of conduction abnormalities and 
symptomology together with an evidence base to assist clinicians in identifying 
patients requiring pacing. 
The following schematics offer clinicians a decision making tool to assist in device 
prescription. 
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Fig. 4.1.1&2 – Decision Tool for Permanent Pacemaker Implantation (Epstein, DiMarco et al. 
2008) with permission Nov 2012 
 
  29 
 
National Institute for Clinical Excellence has also published guidelines for England 
and Wales. These recommendations further emphasise the need for maintenance of 
cardiac conduction physiology: 
“Dual-chamber pacing is recommended for the management of symptomatic 
bradycardia due to sick sinus syndrome, atrioventricular block, or a combination of 
sick sinus syndrome and atrioventricular block, except: 
• in the management of sick sinus syndrome in patients in whom, after full evaluation, 
there is no evidence of impaired atrioventricular conduction; in this situation, single-
chamber atrial pacing is appropriate 
• in the management of atrioventricular block in patients with continuous atrial 
fibrillation; in this situation, single-chamber ventricular pacing is appropriate 
• in the management of atrioventricular block (atrioventricular block alone, or in 
combination with sick sinus syndrome), when patient-specific factors, such as frailty 
or the presence of comorbidities, influence the balance of risks and benefits in favour 
of single-chamber ventricular pacing” (National Institute for Clinical Excellence 
2005) 
 
4.2. Pacemaker Selection 
Having assessed the need for treatment of a bradyarrhythmia requiring permanent 
pacemaker implantation, decisions must then be made as to the type of device. This 
decision must be taken prior to the procedure as this will influence site, access and 
number of leads required. 
For the purposes of treating bradyarrhythmias only, the decision is generally between 
a single or a dual chamber device i.e. a pacemaker with a single lead having an 
electrode in either the atrium or the ventricle, or a pacemaker with electrodes in both 
the atrium and ventricle. 
There is both a cost and procedural benefit from implanting a pacemaker with a single 
electrode: less hardware hence less cost, requires single transvenous access and hence 
less potential for procedural and post procedural risks. 
As already stated there is much evidence supporting physiological pacing, such that 
the pacemaker function mimics that of the native conduction system – sinus 
rhythm.(Lamas, Lee et al. 2002; Newman 2003; National Institute for Clinical 
Excellence 2005). This maintenance of normal cardiac conduction ensures 
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atrioventricular synchrony, physiological pacing increasing cardiac output both during 
exercise and at rest regardless of the status of the left ventricular function. 
 
The British Pacing and Electrophysiology Group (BPEG), together with North 
American Society of Pacing and Electrophysiology (NASPE), developed a generic 
code called the NBG(NASPE/BPEG Generic) code in 1987. (Bernstein 2000)  
This code offers single letter annotation to the chamber of the heart paced, chamber of 
the heart from which sensing can take place, the type of response of the device to 
those paced/sensed events, the availability of further programmable features and 
finally any tachycardia therapy. 
Function I Function II Function III Function IV Function V 
Chamber(s) 
Paced 
Chamber(s) 
Sensed 
Mode of 
response 
Programmable 
functions 
Antitachycardiac 
functions 
V=Ventricle V=Ventricle T=Triggered R=Rate response O=None 
A=Atrium A=Atrium I=Inhibited C=Communicating P=Paced 
D=Dual 
(A&V) 
D=Dual 
(A&V) 
D=Dual-
(Triggered and 
inhibited) 
M=Multiprogrammable S=Shocks 
O=None O-None O=None P=Simple 
programmable 
D=Dual (P&S) 
   O=None  
Table 4.2.1 – Modified from the 1987 NASPE/BPEG Generic (NBG) Pacemaker Code (Bernstein 
2000) 
 
When considering the two main bradyarrhythmias requiring permanent pacemaker 
implantation, SSS/sinus node dysfunction and atrioventricular block, then the above 
annotations would translate as follows: 
o SSS relates to the failure of the sinus node to initiate an impulse either 
permanently or intermittently. The pacemaker requirement would be to 
electrically mimic sinus node electrical activation thus starting the normal 
conduction pathway down to the ventricles.  
In this case the chamber paced would be the atrium – A, the chamber from which 
sensed activity would be required (when the sinus node dysfunction is intermittent) 
would also be atrium – A and the mode of response would be inhibition i.e. if the 
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pacemaker detects a sensed event from the atrium then this would inhibit a pacing 
stimulus. 
If there was the requirement, as is often the case, for rate modulation during activity, 
the rate response would be a required device feature, giving an overall mode of 
operation of AAIR. 
 
o Atrio-ventricular block, as previously described, is a problem with the signal 
from the atria reaching the ventricles, this impulse from the sinus node may be 
delayed, intermittent or completely unable to conduct. 
In this case the chamber not receiving any impulse from the sinus node is the ventricle 
and hence the chamber paced would be ventricle – V, the chamber sensed would be 
both atria and ventricles –D. In order to synchronise ventricular stimulation following 
atrial depolarisation the pacemaker must sense that atrial signal to set an appropriate 
time or atrioventricular delay (<200ms) before pacing the ventricle,  and therefore the 
mode of response in order to maintain AV synchrony would be both triggered (i.e. a 
sensed atrial event would trigger a ventricular paced event) and inhibited – D. Again, 
the need for rate modulation would need to be assessed: if this feature is incorporated 
then the overall operating mode would be VDDR. 
In clinical practice, atrial sensing can most reliably be achieved by having an 
electrode permanently fixed in the atrium. The electrode can either sense of pace, the 
option of having the atrial electrode capability of pacing would generally result in 
programming the device DDD or DDDR – thus giving both atrial and ventricular 
sensing and pacing support. 
Given this methodology of deriving pacemaker mode of operation, the decision of 
which type of pacemaker and mode to implant should be relatively straightforward. 
Clinical practice shows a somewhat different picture for type of device. Although 
much of this could be explained away by the prevalence of mixed conduction 
disturbances, this does not fully justify the picture, certainly in the United Kingdom. 
The next section considers the national pacemaker implanting practice and gives 
clinical insight and justification into the types of pacemakers prescribed. 
 
 
 
  32 
 
4.3. Pacemaker Prescription - The National and Local Context. 
All cardiac devices implanted in England and Wales are reported to the Central 
Cardiac Audit Database (National Institute for Cardiovascular Outcomes Research 
since 2011). This national audit is part of the National Clinical Audit & Patient 
Outcome Programme (NCAPOP), which is managed by the Healthcare Quality 
Improvement Partnership (HQIP).  
This data is shared nationally with the commissioners of cardiac device therapy in the 
Primary Care Trusts and the individual implanting centres via the regional Cardio-
Vascular Networks. Its purpose is to ensure that evidence-based practice is delivered 
equitably across all implanting centres in England and Wales. 
The data on implant rates are further compared to international practice and measured 
against National Institute for Clinical Excellence recommendations for cardiac device 
implant rates. 
One of the key reporting markers is the use of physiological pacemakers. It states in 
the most recent report covering national data submissions for 2009: 
In practice we define physiological pacing as atrial-based pacing, i.e. any pacing 
mode which senses or paces the right atrium. These modes will include: 
 Atrial pacing (whether rate responsive or not modes AAI and AAIR) 
 Dual chamber pacing (whether rate responsive or not modes DDD and 
DDDR) 
 Non-P synchronous pacing with dual chamber sensing (modes DDI and 
DDIR) 
 Managed ventricular pacing modes (MVP, AAIDDD, AAIRDDDR, 
AAIsafeR) 
Atrial based pacing does NOT include: 
 Ventricular inhibited pacing (VVI mode) 
 Ventricular inhibited pacing with rate response (VVIR mode) 
(CRM National Clinical Audit 2009 (Cunningham 2009)) 
 
The Cardiac Rhythm Management (CRM) National Clinical Audit classes 
physiological pacing as “cardiac pacing in which the pacemaker senses or stimulates 
cardiac activity such that it emulates as closely as possible the normally conducted 
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sinus rhythm” it further suggests “the physiological contribution of the atria should 
not be ignored”. (CRM National Clinical Audit (Cunningham 2009)) 
These requirements, although not mandated, are recognised as the preferred 
physiological criteria to be fulfilled when offering permanent cardiac pacemaker as a 
treatment for symptomatic bradycardia, 
During the initial review of data for this research thesis the most up to date implant 
data was 2009, however the 2010 data was released in late 2011. Both sets of data 
have been included as 2009 gave greater detail of implanting rationale, whereas the 
2010 featured greater levels of detail of advanced device data not covered in this 
project. 
It is worth noting that there is debate regarding the accuracy of the coding data 
showing the maximal programmable capabilities of devices as this is an area where 
CCAD completion is inconsistent. 
 
When the data was analysed for the implantation practice for England and Wales in 
2009, it shows a total of thirteen pacing modes were adopted at implant – these modes 
are the maximum possible mode of the implanted device, not necessarily what the 
device was programmed to at discharge.  
 
 
Fig 4.3.1. CRM National Clinical Audit 2009 (Cunningham 2009) 
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By examining the audit returns of all implanting sites in England and Wales the 
following ECG (electrocardiograph) indications were reported for new permanent 
pacemaker implants  by CCAD for 2009: 
 
Complete heart block – 22.1% 
Incomplete heart block – 21.7% 
AF with bradycardia – 23.4% 
Sick sinus syndrome – 26.1% 
Other – 6.7% 
 
Analysis of the modes implanted and pacing indications, when compared to 
AHA/ACC/HRS guidelines as the basis for these decisions, allows the following 
conclusions to be drawn: 
The vast majority of patients implanted in 2009 had rate response as a feature (as 
detailed in Section 3.2.1. - this programmable feature modulates the pacing rate 
depending on the detection of activity). This is normally a feature associated with 
sinus node dysfunction or chronotropic incompetence. 
If we consider the atrial based systems, 44% of patients had impaired atrio-ventricular 
conduction (complete and incomplete AV block). 
 AF with bradycardia, providing the AF is chronic, has no synchronous atrial activity, 
the atrial rates exceed 300 bpm and natively conducts irregularly. Pacing is indicated 
when the conduction to the ventricles is chronically slow due to AV block or 
bradycardia as a result of necessary drug therapy. 23.4% of patients had an indication 
of AF with bradycardia for which the only pacing mode is VVI +/- R, however 33% 
received ventricular based devices. This would suggest a non-physiological 
prescription of VVI/R for 10% of new implants. 
The most staggering conclusion is that 26% of patients had an indication of sick sinus 
syndrome but <1% received pure atrial pacing devices only (AAI) and less than 1% 
received new minimal ventricular pacing devices (AAI DDD).  
 
The CRM National data is further broken down into regional data, offering audit of 
individual implanting centres within a Cardio-Vascular Network or Strategic health 
Authority. 
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The data below are taken from Clinical Audit of Heart Rhythm Device Implantation 
2009 for the North of England Cardiovascular Network. Further research took place 
within the Network: it is useful to measure implanting practice within this locality 
area and how it matches the national picture. 
 
Fig 4.3.2. Mode/Device Prescription – North of England Cardiovascular Network (Cunningham 
2009), with permission 
 
The NECVN mode selection for 2009 is very similar to the national mode selection 
data for 2009. There were 7 implanting centres in the North East of England in 2009. 
There are no significant outliers in terms of device use between the implanting centres 
in the North of England, with higher than average performance in use of atrial based 
systems from Dryburn Hospital (known as University Hospital of North Durham and 
part of this research project), performance likely influenced by lowest proportion of 
VVIR devices suggesting either high performance against the use of atrial based 
pacing or a relatively lower prevalence of atrial fibrillation with bradycardia in 
Durham. 
 
Since the original literature review, the data for the implanting year of 2010 have been 
published. This data shows a broadly similar use of modes between the 2 years with 
an increase in the use of rate response, but there remains an under-utilisation of single 
AAI/AAIR or the newer AAIR DDDR devices (R denotes use of rate response). 
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Fig 4.3.3 CRM National Clinical Audit 2010 *permission granted April 2011(Cunningham 
2010),  
  
There is little difference in implanting practice nationally between 2009 and 2010. 
The implantation of DDDR is up from 53.05% to 60.5%, there is very little change in 
the use of AAI/AAIR with both remaining <0.5%, and the use of the more novel 
programming mode options of AAIDDD and AAIRDDDR has risen minimally 
and still at less than 0.1%. 
 
It is worth comparing our local Network data for 2010 to see if evidence or device 
development has influenced practice between years 2009 and 2010. 
 
 
Fig 4.3.4. Mode/Device Prescription – North of England Cardiovascular Network (Cunningham 
2010) 
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The NECVN mode selection for 2010 is very similar to the national mode selection 
data for 2010 and also for local implanting data for 2009 but with10% increase in use 
of DDDR and decrease in use of DDD. 
Dryburn (UHND) still remains the highest performer in the use of atrial based 
systems. 
As previously described the ® represents the use of rate response. This increase may 
not necessarily represent an increased prevalence of sinus node dysfunction and 
chronotropic incompetence, but rather a tendency to use rate response in all presenting 
bradyarrhytmias to ensure that the development of chrontropic incompetence at a later 
stage would allow the opportunity to utilise rate response rather than having to 
perform a pacemaker change, a further surgical procedure, to access this feature.  
 
The questions developing from this data required further understanding and evidence 
supporting the mode decisions for patients with a pacemaker indication of sick sinus 
syndrome, for which the mode of AAI +/- R would be the expected mode of choice 
(Section 4.2). 
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Chapter 5– Effects of Long-Term Ventricular Pacing 
5.1. Electrical and Mechanical Effects of RVA Pacing 
“Fifty years after its introduction, cardiac pacing for symptomatic bradycardia can 
look back on its impressive past. It is one of those rare medical therapies that has 
changed the lives of numerous patients faced with a disease with high morbidity and 
mortality to a prognosis which almost equals that of the normal population. 
Associated with a steep increase in life expectancy in the industrial world during the 
last half century, the number of device implants has been steadily growing and is 
expected to grow even further. Because of the clear benefits of cardiac pacing in 
patients with symptomatic bradycardia, potential harmful effects of pacing have only 
recently been recognised.”(de Cock 2008) 
This statement from a commentary by C.C.de Cock in 2008 entitled “fifty years of 
pacing: the dark side of the moon?” suggests that pacing is not a treatment without 
potential longer term harmful effects on heart function. 
A number of recent research trials and clinical evidence has suggested that there is a 
correlation between long term right ventricular apical (RVA) pacing and the 
development and worsening of heart failure symptoms and hospitalisation (Manolis 
2006). 
This same commentary went on to suggest that avoiding ventricular pacing, 
specifically in those patients for which ventricular pacing was not the primary reason 
for the implant, should be established by whatever contemporary pacing procedure or 
programming was available. 
 
The avoidance of ventricular pacing in atrioventricular block and atrial fibrillation 
with bradycardia is dependent on the degree of chronic pacing support that is 
required. 
If the atrioventricular block is intermittent, then pacing support is only required when 
the signals from the sinus node intermittently fail to conduct through the AV node to 
the ventricles. 
In pure sinus node dysfunction, there should be no need to pace the ventricle though 
there is evidence of conduction disease progression that can result in patients with 
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sinus node dysfunction going on to develop AV block, AV nodal or distal His bundle-
Purkinje conduction system disease can be co-existent in up to 30% of patients 
(Ellenbogen and Wood 2008 pp:19). 
The Danish AAI vs VVI trial noted “the risk of AV block was approximately 0.6% per 
year, which is equivalent to the risk found in a larger meta analysis. This is only a 
little higher than the risk of AV block in the aged matched non-paced 
population.”(DANPACE 2009)  
There have been a number of large scale trials investigating the effect of pacing the 
right ventricle in isolation, with or without atrioventricular synchrony. 
As detailed in Section 3.4, the ventricular electrode is placed in the right ventricular 
apex (RVA) generally using a passive fixation mechanism pushing the electrode tip 
into the trabecular apex of the RV. 
The pathophysiology of the detrimental effects of RV apical pacing is attributed to 
these abnormal electrical activation sequence and hence mechanical activation 
patterns of the ventricles.  This results in a delay in the activation sequence, much in 
the same way as left bundle branch block, where the activation of the RV myocardium 
takes place before the LV myocardium. This delay in ventricular activation manifests 
as a broader QRS on the surface ECG during pacing.(Kass 2002)  
This delay is characterised by early activation of the septum with the final activation 
being in the basal infero-posterior area of the LV. 
This delayed electrical sequence results in a change in the mechanical pattern of 
contraction. Whereas the ventricles would contract in a simultaneous manner in 
normally conducted intra-cardiac signalling, the ventricular contraction becomes 
dyssynchronous with RV apical pacing and consequential conduction delay. 
“This abnormal contraction pattern of the regions of the LV may result in a 
distribution of myocardial strain/work and subsequent less effective 
contraction”(Tops, Schalij et al. 2009) 
A sub-study of MOST (Mode Selection Trial) showed a strong association between 
RV pacing and risk of heart failure hospitalisation as well as the development of atrial 
fibrillation in both the physiological DDD mode and single chamber VVI mode, 
although the risks were somewhat higher in the single chamber VVI modes .(Lamas, 
Lee et al. 2000)  
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5.2. Physiological Effect of RVA Pacing 
The table below details some of the adverse effects of RV apical pacing as suggested 
by Tops et al – RV Apical Pacing and Dyssynchrony (Tops, Schalij et al. 2009) 
 
Metabolism/Perfusion Changes in regional perfusion 
Changes in oxygen demand 
Remodelling Asymmetrical hypertrophy 
Histopathological changes 
Ventricular dilation 
Functional mitral regurgitation 
Haemodynamics Decreased cardiac output 
Increased LV filling pressures 
Mechanical Function Changes in myocardial strain 
Interventricular mechanical dyssynchrony 
Intraventricular mechanical dyssynchrony 
Table 5.1 – Acute and Long-Term Effects of RV Apical Pacing. (Tops, Schalij et al. 2009) 
 
Mechanical cardiac dyssynchrony is associated with increased risk of cardiac 
mortality and morbidity in the heart failure population. 
RV apical pacing can result in both interventricular (between RV and LV) mechanical 
dyssynchrony and intraventricular dyssynchrony (within the LV). The existence or 
degree of dyssychrony can be assessed using cardiac ultrasound and utilising Doppler 
tools that can look at delayed ejection times and late activation of LV walls. 
RV apical pacing, with or without AV synchrony, reduces stroke volume and results 
in significant regional myocardial perfusion defects hence reducing myocardial 
efficiency.  
These effects can lead to ventricular-remodelling, which refers to adaptations of 
myocardial contractility and symmetry – this can lead to atypical segmental 
thickening or hypertrophy, thinning and overall cardiac dilatation which in turn leads 
to impaired systolic and diastolic function. (Thambo, Bordachar et al. 2004; Tops, 
Schalij et al. 2009) 
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Given these potentially catastrophic effects on cardiac performance, there have been a 
number of large scale clinical trials looking at the effects of differing pacing mode 
strategies, which are discussed in the following section. 
Zhang et al (2008) performed a study of 304 patients paced for acquired AV block 
and suggested that “after a median follow-up of 7.8 years, permanent RV apical 
pacing was associated with heart failure in 26% of patients”(Zhang, Chen et al. 
2008) 
Abdul Al-Hesayan et al suggested that the effects of RVA pacing on the cardiac 
activation sympathetic system was a possible cause of the reduction in cardiac 
contraction efficiency and subsequent development of cardiac functional impairment 
in what were previously normally functioning hearts.(Al-Hesayen and Parker 2006) 
A number of studies have suggested that ventricular dyssynchrony may be present in 
up to 50% of patients following long term RVA pacing with a greater prevalence in 
those patients with underlying cardiac impairment, and that the presence of 
mechanical dyssynchrony is associated with LV dilation and functional impairment. It 
remains unclear if the dyssynchrony is an acute phenomena post RV apical pacing 
that ultimately leads to LV functional impairment and longer term heart failure. 
It is also unclear why some patients develop dyssynchrony with RV apical pacing and 
some do not. The PROSPECT trial looked at echocardiographic parameters employed 
to predict the responders to cardiac resynchronisation therapy and suggested that some 
echo techniques are not sensitive enough to detect small changes in electromechanical 
activation.(Chung, Leon et al. 2008)  
It is also worth noting that these deleterious effects on ventricular function are not 
universal amongst the pacemaker population. 
 
 
5.3. Bi-Ventricular Pacing 
In order to reduce adverse effects or prolonged right ventricular pacing due to 
conduction delay and resultant mechanical dyssynchrony, device technology has 
developed bi-ventricular pacing to allow for simultaneous left and right ventricular 
activation. This type of therapy requires the placement of a pacing electrode and wire 
into the right ventricle in the same way as normal pacemakers, with the addition of a 
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wire in or on the left ventricle and usually the placement of an atrial wire to ensure 
atrioventricular synchrony.  
This procedure is technically more challenging; it can result in higher levels of 
complications and is considerably more expensive.(Ellenbogen and Wood 2008 pp: 
65-66) 
Due to the degree of evidence of the deleterious effects of RV pacing in the presence 
of pre-existing heart failure due to ventricular impairment, this type of therapy has 
been reserved for patients at the more severe end of the spectrum of mechanical heart 
failure. 
The publication of the results of the recent PACE trial – Pacing to Avoid Cardiac 
Enlargement, suggested that bi-ventricular pacing is superior to RV pacing in patients 
with normal or preserved cardiac function, concluding that the “Left ventricular 
adverse remodelling and deterioration of systolic function continues at the second 
year after RVA pacing. This deterioration is prevented by BiV pacing”.(Chan, Fang et 
al. 2011) 
The impact of this research is yet to be established into mainstream clinical practice 
for pacing in bradycardia, with bi-ventricular pacing remaining an option for those 
with poor pre-existing cardiac function and symptoms of heart failure in the presence 
of a native broad QRS complex. 
 
 
5.4. Effects of Pacing from other RV Sites 
There have been a small number of trials looking at varying the RV pacing site and 
the effect this has on the electromechanical activation sequence and hence the 
presence of dyssynchrony. 
Although RV apical pacing remains the stimulation site of choice in the vast majority 
of the pacemaker population, there are other potential RV sites for stimulation: right 
ventricular outflow tract (RVOT), RV septum or para-Hisian regions of the RV 
septum do offer theoretical electrical activation advantages over RV apical pacing. As 
the pacing stimulus originates from higher up in the electrical conduction system, this 
should result in a narrower paced QRS complex due a more simultaneous activation 
of RV and LV.  
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Direct His-bundle pacing offers the greatest effect on paced QRS complex closely 
mirroring the narrow complex of normal sinus rhythm and normal interventricular 
conduction, however this is technically very challenging. In five published studies, 
His-bundle pacing was only achieved in <70% of patients attempted.(Sweeney and 
Prinzen 2006) 
The majority of studies on alternative RV pacing sites have used the septal portion of 
the RVOT, however the reported results of many of the randomised trials have shown 
equivocal differences compared to RV apical pacing.(Mera, DeLurgio et al. 1999; 
Nikoo, Ghaedian et al. 2011)  
A number of potential explanations have been suggested for this relatively minor 
difference in outcome between RVOT and RVA pacing: technically it is difficult to 
identify the RVOT site via fluoroscopy, there were only small patient numbers and 
there were variations in the baseline cardiac function prior to pacing in these cohorts. 
It was also further noted that the most effective pacing site may vary from patient to 
patient, and may not always be in the outflow portion of the RV septum. 
It is clear that optimum RV lead placement for improved cardiac synchronisation 
requires larger and longer term prospective studies to establish whether RVA, septum 
or RVOT pacing has the best outcomes in terms of preserving ventricular function. 
(Harris 2000) 
 
It is clear that pacemaker prescription decisions are complex and multi-factorial, and 
that the impact of long term pacing on patient outcomes should always play a part in 
the decision making process. It is worth considering some of the larger and frequently 
quoted randomised clinical trials relating to device prescription and some of the 
outcomes. 
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Chapter 6 – Randomised Clinical Trials in Cardiac Device 
Mode/Prescription. 
6.1. Canadian Trial of Physiological Pacing (CTOPP). 
The remit of this large scale randomised clinical trial sought to compare physiological 
or atrial based pacing and ventricular based pacing systems. 
The primary outcomes of this trial were cardiovascular death or stroke, the total 
cohort compromised 2568 patients with symptomatic bradycardia, of whom 1474 
were randomly assigned ventricular based pacing (VVI/R) and 1094 assigned 
physiological pacing (AAI/R or DDD/R). (Kerr, Connolly et al. 2004) 
This trial excluded those patients in chronic atrial fibrillation, patients <18 years of 
age or patients not expected to live beyond 1 year following implant. 
As previously discussed, physiological or atrial pacing indicates a system that 
maintains the normal atrioventricular synchrony of the heart – such as an atrial paced 
and sensed pacemaker with normal atrioventricular conduction or an atrial and 
ventricular paced and sensed system.  
A ventricular based pacing system refers to pacing and sensing from the ventricle only 
without any maintenance of normal atrioventricular synchrony. 
The outcome of this trial reported  “no significant reduction in cardiovascular death 
or stroke from physiological pacing occurred during a mean follow-up period of 6.4 
years” (Kerr, Connolly et al. 2004) 
The most significant outcome was a 6.4% absolute reduction in the incidence of atrial 
fibrillation in the atrial based cohort compared to the ventricular based cohort.  
Gillis et al suggested that it is not atrial based pacing that prevents the development of 
atrial fibrillation but that ventricular based pacing promotes the development of atrial 
fibrillation.(Kerr, Connolly et al. 2004; Gillis, Kerr et al. 2005) 
This association between pacing mode and the development of atrial fibrillation 
should be explored in relation to the mode and programming of the research cohort in 
County Durham and Darlington to evaluate the relationships between programmed 
mode/algorithm and the prevalence of atrial fibrillation. 
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6.2. Mode Selection Trial in Sinus Node Dysfunction – MOST 
This was a 6 year randomised control trial involving 2010 participants comparing dual 
chamber rate responsive pacing to single chamber ventricular pacing in patients with 
sinus node dysfunction.(Lamas, Lee et al. 2000; Sweeney, Hellkamp et al. 2003)  
The purpose of this clinical trial was to discover if dual chamber rate responsive 
pacing was superior to single chamber ventricular pacing in terms of adverse effects 
such as stroke, quality of life and function and cost effectiveness in patient with sick 
sinus syndrome. 
The trial concluded “in sinus-node dysfunction, dual-chamber pacing does not 
improve stroke-free survival, as compared with ventricular pacing. However, dual-
chamber pacing reduces the risk of atrial fibrillation, reduces signs and symptoms of 
heart failure, and slightly improves the quality of life. Overall, dual-chamber pacing 
offers significant improvement as compared with ventricular pacing”(Lamas, Lee et 
al. 2000; Lamas, Lee et al. 2002) 
Indeed further analyses of the original MOST study by Sweeney M.O. et al on 
Adverse Effect of Ventricular Pacing on Heart Failure and Atrial Fibrillation Among 
Patients With Normal Baseline QRS Duration in a Clinical Trial of Pacemaker 
Therapy for Sinus Node Dysfunction, concluded that ventricular pacing, even with 
maintenance of atrioventricular synchrony, increases the risk of heart failure 
hospitalisation and the risk of atrial fibrillation in patients with sinus node 
dysfunction. (Sweeney, Hellkamp et al. 2003) 
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Fig 6.2.1 Risk of Heart Failure Hospitalisation due to RVP and the risk of AF due to RVP. When RVP 
is less than 40% for each 10% rise in RVP there is a 54% relative increase in heart failure 
hospitalisation, however when RVP exceeds 40% then the risk remains constant. Furthermore AF 
increases linearly as RVP rises.  (Sweeney, Hellkamp et al. 2003) *permission for re-use 
granted 
 
MOST offers further evidence of the deleterious effects of RV pacing, and in addition 
suggests that the maintenance of atrioventricular synchrony does improve outcomes 
and reduces the incidence of atrial fibrillation. It does not, however, compare single 
chamber atrial pacing to dual chamber pacing which are the prescribed modes for 
pacing in sick sinus syndrome. Single chamber ventricular pacing in SSS is not 
recommended by NICE or AHA/HRS guidelines for device prescription in SSS. 
 
6.3. Pacemaker Selection in the Elderly - PASE 
This study again looked at the comparison of single chamber ventricular pacing 
compared to dual chamber synchronous pacing in the elderly population investigating 
clinical outcomes. 
407 patients were investigated in a single blinded randomised trial over a 30 month 
period. 
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This study also further confirmed improved clinical outcomes in patients with dual 
chamber synchronous devices over single chamber ventricular devices, especially in 
those patients with sinus node dysfunction.(Lamas, Orav et al. 1998) 
 
6.4. Single-Chamber versus Dual-Chamber Pacing for High-Grade 
Atrioventricular Block - UKPACE 
This study, also relating to mode selection, was specifically for patients with implant 
aetiology of atrioventricular block. 
The study enrolled 2021 patients with new implants for atrioventricular block and 
compared the use of single chamber ventricular pacing with dual chamber 
synchronous pacing. 
The results of this trial indicated no statistical difference between the two pacing 
strategies in terms of rates of atrial fibrillation, heart failure, stroke or other 
thromboembolic events. 
This was a rather different outcome to other major trials in terms of clinical benefits 
and all-cause mortality, however this trial only considered patients requiring pacing 
for atrioventricular block.(Toff, Camm et al. 2005) 
 
These major trials have all given influence to the national and international guidelines 
on device and mode prescription, and given evidence for the development of device 
algorithms and programming rationale.(Tse and Lau 2006) 
 
6.5. Trials Specifically Investigating Mode Selection in Sick Sinus Syndrome 
Kristensen et al compared single chamber atrial pacing and dual chamber rate 
responsive pacing in 177 patients with sick sinus syndrome, in a trial looking for the 
incidence of atrial fibrillation and thromboembolism between the two main modes. 
This trial also considered dual chamber pacing with atrioventricular delay either 
‘short’ or ‘long’. 
The conclusions of this trial stated that the outcome in terms of burden of atrial 
fibrillation was significantly reduced in AAIR with an incidence of 7.4% compared to 
23.3% in dual chamber with AV delay ‘short’ and 17.5% in dual chamber AV delay 
‘long’. 
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This result could well be explained in the terms of degree of ventricular pacing such 
that in AAIR there would be no ventricular pacing, but in DDDR with short AV delay 
there was 94% ventricular pacing and 14% in the AV delay long group.(Kristensen, 
Nielsen et al. 2004). 
This trial was curtailed early due to the commencement of the DANPACE trial. 
 
DANPACE looked specifically at comparing the outcomes in terms or mortality, heart 
failure, incidence of paroxysmal and chronic atrial fibrillation and rate of re-operation 
in a randomised population of 1415 patients with sick sinus syndrome randomly 
assigning either atrial paced and sensed systems- AAIR and dual chamber rate 
responsive systems-DDDR.(DANPACE 2009) 
The conclusions suggest that there is no statistically significant difference between the 
two modes in terms of all-cause mortality (primary end point), and no statistically 
significant differences in the incidence of heart failure and chronic atrial fibrillation 
and stroke (secondary end points). However there was a statistically significant 
difference in the incidence of paroxysmal atrial fibrillation with AAIR having less 
paroxysms (p-value 0.042), and difference in the requirement for re-operation in 
favour of DDDR (p-value <0.001). 
The DANPACE investigators went on to conclude that due to the need for re-
operation, dual chamber rate responsive pacemakers (DDDR) should be the mode of 
choice for patients with sick sinus syndrome.(Nielsen 2010) 
 
Anderson HR et al conducted a randomised prospective trial of 225 consecutive 
patients with sinus node dysfunction who were randomised to either atrial or 
ventricular pacing. These patients were followed up over a 5 year period. It concluded 
that “patients with sick-sinus syndrome should be treated with atrial pacing rather 
than ventricular pacing because atrial pacing is associated with lower frequencies of 
atrial fibrillation, thromboembolic complications, and a low risk of atrioventricular 
block”(Andersen, Thuesen et al. 1994). 
6.6. Conclusions from Major Pacemaker Mode Trials 
It is clear from the review of major trials into the efficacy of pacemaker mode 
decisions that considerable research has been undertaken into comparing single 
chamber ventricular pace devices to synchronous dual chamber pacing. 
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Although the evidence is not compelling in favour of dual chamber devices in terms 
of all-cause mortality, there is consistent evidence for the reduction of the burden of 
atrial fibrillation with dual chamber synchronous pacemakers. 
According to National Institute for Health and Clinical Excellence” atrial fibrillation 
is the most common sustained arrhythmia and if left untreated is a significant risk 
factor for stroke and other morbidities (National Institute for Health and Clinical 
Excellence CG/36- 2006) 
MOST was the only major trial looking at mode selection in patients with sick sinus 
syndrome: conclusions suggested dual chamber superiority over single chamber 
ventricular pacing in terms of reduced atrial fibrillation burden and heart failure 
hospitalisation. 
There are fewer trials comparing single chamber atrial pacing to dual chamber pacing 
in sick sinus syndrome with DANPACE by far the largest and most cited research. 
Its conclusions support the use of dual chamber devices mainly because of the 
prevalence of re-operation. This is likely due to the development of atrioventricular 
block requiring ventricular pacing at a later stage, but as described below, there is 
conflicting evidence on development of atrioventricular block in the SSS population. 
This research seems to confirm the underlying implanting practice of the UK, where 
patients with sick sinus syndrome are rarely implanted with single chamber atrial 
systems in favour of dual chamber systems with the rationale relating to the small risk 
of re-operation to implant a ventricular lead due to the development of atrioventricular 
block. 
It is suggested that clinical risk stratification that can be undertaken in patients with 
SSS to evaluate the risk of developing atrioventricular block. The use of 
atrioventricular Wenckebach rates have been routinely used as a predictor suggesting 
that an atrial paced rate of >120bpm with maintenance of a 1:1 atrial to ventricular 
conduction rate was a predictor of reduced risk of development of atrioventricular 
block. (Masumoto, Ueda et al. 2004) 
However Haywood et al found that Wenckebach rates over 120bpm did not correlate 
well with reduced rates of development of atrioventricular block.(Haywood, Ward et 
al. 1990) 
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Anderson et al also suggested that low intraoperative Wenckebach rates were a poor 
predicator of the development of atrioventricular block but did suggest that these rates 
remained stable throughout longer term follow-up.(Andersen, Nielsen et al. 1998) 
Brandt et al suggest that the use of AAI devices in SSS can be successfully applied in 
the absence of advanced bundle branch block, and that routine use of DDD devices in 
these patients is not warranted in the natural history of SSS.(Brandt, Anderson et al. 
1992) 
The levels of conflicting evidence for the likelihood of development of 
atrioventricular block in the sick sinus population seems to give credence to the 
implanting practice in the United Kingdom and indeed in the North East of England, 
as stated in Section 4.3, despite the recommendations for bradycardia pacing stated in 
the NICE technical appraisal document.(NICE 2005) 
The overwhelming evidence of the potential for adverse effects of long term 
ventricular pacing on the development or worsening of heart failure, as stated in 
Chapter 5, has resulted in device manufacturers offering programming strategies and 
specific algorithms to minimise the likelihood of ventricular pacing in dual chamber 
systems. 
The following chapter seeks to review the strategies undertaken by pacemaker 
companies to offer implanting and follow-up centres algorithms that will maintain 
atrioventricular synchrony whilst mitigating the risk of the development of AV block.  
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Chapter 7 – Review of Available Pacemaker Algorithms 
7.1. Post Implant Programming Options  
Modern pacemakers have a number of programmable features depending on the type 
and general sophistication of the device. 
In the sinus node dysfunction population it is recommended that physiological or 
atrial based pacemakers are implanted (NICE 2005; Epstein, DiMarco et al. 2008). As 
described in the previous section, conflicting evidence exists on the use of a single 
chamber atrial pacemaker as the system of choice in SSS,  and this is certainly in 
evidence from the implanting report from the National Database (Brandt, Anderson et 
al. 1992; Cunningham  2009; Cunningham 2010). 
Modern dual chamber pacemakers have multi-programmable options to allow for 
adjustments depending on the implanting rationale, underlying rhythm following 
pacemaker implant, lead integrity and battery maintenance. 
The main feature that was to be considered within this research project was the 
atrioventricular delay (AVD). This feature mimics the normal delay between the start 
of atrial systole and the start of ventricular systole: this brief delay (between 120 -210 
milliseconds) allows for maximal ventricular filling prior to systolic ejection 
(Ellenbogen and Wood 2002 pp:303-307). 
The AVD can be programmed nominal or longer than physiological. In most 
pacemakers the nominal (boxed or factory programmed settings) is between 150 and 
170ms. The haemodynamically optimal AV delay, which corresponds to the intrinsic 
PR interval is 120 – 210ms at rest in the average patient with normal ventricular 
function. (Ellenbogen and Wood 2010 p:1). 
The programming options for AV delay is dependent on the model of device 
implanted but this may be: 
 Programming the AV delay longer than nominal i.e. greater than 150 -170ms 
 Programming an AV search algorithm which extends the AVD automatically 
 Programming the AVD long and adding an AV search algorithm 
 Programming a mode such as managed ventricular pacing MVP™ or SafeR™  
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7.2. Atrioventricular Delay Programming 
As previously described, lengthening the AVD will encourage or offer sufficient 
opportunity for normal intrinsic atrioventricular conduction in patients with sick sinus 
syndrome. 
There are potential haemodynamic compromises of a longer than physiological AV 
delay, such that there is inadequate ventricular filling due to early or premature mitral 
valve closure, truncating the diastolic filling time and hence reduced cardiac 
output.(Harris 2000; Ellenbogen and Wood 2008 pp:117-9).  
Long AV delays and their haemodynamic relationships can cause symptoms in 
patients, generally termed as pacemaker syndrome. These symptoms can include 
malaise, general fatigue, light-headedness and dizziness. Although pacemaker 
syndrome is rare, and more often associated with loss of atrioventricular synchrony 
commonly associated with single chamber ventricular pacing (VVI) (Ellenbogen and 
Wood 2008 pp:142-3); it should be considered if present with long or very long AV 
delays. Sulke et al found that an AV delay of 175ms offered the most appropriate 
timing based on symptomology and in terms of cardiac performance as assessed by 
echocardiography (Sulke, Chambers et al. 1992) 
 
There are often trade-offs in terms of functionality of the device if the AV delay is 
hard-programmed ‘long’. 
There are features within dual chamber devices that will prevent the tracking of rapid 
atrial arrhythmias such that, if a pathological atrial arrhythmia occurs, it will prevent 
the ventricular stimulation from following or tracking that rapid atrial rhythm. This is 
termed the maximum tracking rate. This function also limits the degree of 
atrioventricular delay that can be programmed due to integral programming conflicts. 
As a result of this safety feature preventing ‘pacemaker runaway’, the ability to track 
faster physiological rates is limited if the atrioventricular delay is long. 
It is physiologically appropriate to have a rate responsive atrioventricular delay that 
mimics the normal PR interval as it shortens by 20-50ms for every 10 beat 
physiological increase in heart rate. This algorithm effectively works in conflict with 
hard programmed AV delay ‘long’ (Ellenbogen and Wood 2008 pp:305). 
The ability for dual chamber pacemakers to switch modes in the presence of atrial 
fibrillation is an accepted requirement of these types of sophisticated devices in order 
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to reduce the risk of inappropriate upper rate tracking. A long atrioventricular delay 
reduces the window for detection of atrial fibrillation and as such can reduce the 
effectiveness of mode switch from dual chamber synchronous pacing to single 
chamber ventricular pacing in the presence of atrial fibrillation. 
Nielsen et al performed a small scale trial of 38 patients programming the 
atrioventricular delay to 300ms. The outcomes showed that in approximately one third 
of patients this strategy was ineffective at reducing ventricular pacing and furthermore 
caused endless loop tachycardias in 5 patients due to retrograde ventricular-atrio 
conduction. Nielsen et al,  therefore, could not recommend hard programmed long AV 
delays in sick sinus syndrome.(Nielson, Pederson et al 1999) 
Endless loop tachycardia is a non-physiological phenomena experienced when there is 
ventricular to atrial conduction, this signal is then tracked and causes the pacemaker 
to pace at the maximum rate. There are programmable features to counteract this 
abnormality of function. 
 
7.3. Atrioventricular Search Algorithms 
In response to the resulting haemodynamic and device interactions of programming a 
long atrioventricular delay and the overwhelming evidence of the deleterious effects 
of unnecessary ventricular pacing, pacemaker companies developed specific 
algorithms to reduce the need to ventricular pace whilst maintaining atrioventricular 
synchrony. 
Typically the device is programmed with a nominal AVD during pacing, for example 
170ms, then a programmable delta value is applied, this may be a duration or a 
percentage value. Using the example of 170ms base AVD, if search or AV hysteresis 
was programmed to a value of 100ms then the device would allow the timing of the 
AVD to extend to 270ms to allow for intrinsic conduction. 
Different manufacturers utilise slight variations in this algorithm in order to actively 
seek intrinsic AV conduction; there has been reported reduction in RV from 97% to 
23% using these algorithms (Bastian and Fessele 2012). 
The advantage of AV search allows for a more flexible and dynamic management of 
the AVD, with periodic AVD extension as conduction through the AV node varies. It 
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also will prevent the need for longer than physiological AV delays and the associated 
risks of endless loop tachycardias and delayed mode switching. 
 
7.4. Atrioventricular Delay Long and AV Search 
There are opportunities to programme both features, having the base AVD long and 
also add a degree of search. This is quite an aggressive strategy and in some devices 
can extend the AVD up to 400ms. 
The haemodynamic consequences and programming conflicts obviously apply to this 
programming strategy, the benefits of maintaining atrioventricular synchrony and 
intrinsic conduction must be balanced against the potential for these haemodynamic 
consequences.(Harris 2000; Ellenbogen and Wood 2008) 
 
 
7.5. Minimal Ventricular Pacing (MVP) 
There are a number of device manufacturers that have produced pacemakers with 
specific minimal ventricular pacing algorithms. The companies use differing 
algorithms terms but they effectively operate in an AAI mode with a back-up mode of 
DDD. The specific minimal ventricular pacing devices used in CDDFT are Medtronic 
MVP (managed ventricular pacing) and Sorin SafeR. 
 
Medtronic have a number of devices with this specific algorithm: the Adapta DR and 
the Ensura DR are two of these devices that are used in County Durham and 
Darlington pacemaker services.  
These devices operate as atrial based pacing with a back-up of ventricular pacing in 
the presence of atrioventricular block AVB. When atrial conduction to the ventricles 
is blocked for two out of four atrial to atrial depolarisation (whether paced or sensed), 
then the devices switches to DDD (atrial and ventricular synchronous pacing). The 
device operates within the programmed AVD and after 1 minute the device checks for 
normal intrinsic AV conduction, if this is found the device switches back to AAI, if 
there is no intrinsic conduction it remains in DDD but checks every 2 minutes 
incrementally (2, 4, 8 etc. up to 16 hours).( Milasinovic, G. Tscheliessnigg, K. et al. 
2008; Medtronic Incorporated 2010) 
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This mode is classed using the national coding system as AAIDDD – rate response 
is generally used as this mode is recommended in patients with SSS, which is requires 
rate regulation due to chronotropic incompetence. (Bernstein 2000) 
The other manufacturer of  minimal ventricular pacing devices used in the CDDFT 
pacemaker service are Sorin SafeR™, Sorin is the manufacturer and SafeR™ is their 
specific algorithm. There are two devices identified in this research from Sorin that 
have the SafeR™ algorithm: these are the Reply DR and the Symphony DR. 
The Sorin algorithms are more complex and sophisticated, switching from AAI to 
DDD depending on the type of atrioventricular block the device detects. 
First degree AV block is tolerated up to a pre-programmed AV delay limit and will 
switch to DDD if there are/is: 
i. Six consecutive abnormal AR/PR (atrial paced to intrinsic R wave or atrial 
sensed to intrinsic R wave) intervals 
ii. Three blocked atrial events in the last 12 beats, or cardiac cycles 
iii. Two consecutive blocked atrial events 
iv. A ventricular pause of up to a programmable limits of between 2 and 4 
seconds 
The device remains in DDD making attempts to return to AAI providing normal AV 
conduction is restored.(Davy, Hoffmann et al. 2012; Sorin Group 2012) 
There are circumstances for normal device function and intrinsic conduction to 
inappropriately cause SafeR to switch into DDD mode, most commonly early intrinsic 
events and extra beats falling in the refractory period. 
 
There have been reports of patient symptoms associated with MVP algorithms, 
ranging from chest pain to dizziness.  
A study by Murukami et al in 2010 enrolled 141 patients, randomly assigned to either 
AV search or MVP, reported two patients having symptoms due to the algorithms 
programmed (1%), one with MVP and one with AV search.(Murakami, Tsuboi et al. 
2010) 
The SAVE PACe trial for patients with symptomatic bradycardia due to SSS 
compared dual chamber pacing with AV search and MVP algorithms with primary 
outcome of development of AF. This study was terminated prematurely due to early 
achievement of the end points in terms of development of atrial fibrillation and RV 
  56 
 
pacing differences between 99% in the DDD group to 9% in the MVP group.(Bastian 
and Fessele 2012) 
 
It is clear that symptoms must be monitored and correlated to device activity to assess 
any negative effects of device programming. There have been some adverse reports 
from the use of MVP devices as reported by Murukami et al (2010), and van 
Mechelen and Schoonderwoerd in 2006  reported one pro-arrhythmic complication 
requiring external defibrillation, both cited by Bastian and Fessele 2012. 
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Chapter 8 – Research Objectives 
8.1. Review of Key Issues from Literature 
The previous sections have sought to place the topic of interest into a clinical context, 
and thus identifying pertinent research questions which need addressing. 
There are a number of key issues that have been highlighted by the literature review: 
I. Sick sinus syndrome refers to an impairment of the automaticity of the sinus 
node, however in many patients the electrical conduction pathways beyond the 
sinus node remains intact. Permanent pacemaker implantation is the treatment 
of choice for symptomatic patients with sinus node dysfunction, with the 
requirement for atrial/sinus node artificial stimulation and hence a single 
chamber device for atrial sensing and atrial pacing (AAI). 
II. National and local data suggests the pacemaker mode of choice for patients 
with sick sinus syndrome is dual chamber pacing (DDD) such that there is 
atrial and ventricular pacing function in a synchronous way. This accounts for 
failure of sinus node automaticity but also conduction abnormalities below the 
sinus node at atrioventricular node level. This is despite evidence showing a 
less than 1% per year incidence of atrioventricular conduction 
problems.(DANPACE 2009) 
III. There is considerable clinical and research evidence that right ventricular 
pacing, either synchronous or asynchronous, can have a deleterious effect on 
ventricular function which can lead to heart failure, especially in the presence 
of pre-existing cardiac dysfunction. There is further evidence of increase in 
prevalence of atrial fibrillation which in turn can increase the risk of stroke. 
IV. There are pacing algorithms available as programmable options on modern 
pacemaker systems that can reduce, to varying extents, the amount of 
ventricular pacing. This can involve extending the atrioventricular delay to 
allow intrinsic atrioventricular nodal activation or by operating in AAI mode 
(atrial paced and sensed) which will automatically switch to DDD temporarily  
in the absence of normal atrioventricular conduction in either 2 out of 4 beats 
or 3 beats out of 12 (Sorin Group 2012/Medtronic Inc. 2010). 
 
  58 
 
The objectives of the research were to offer evidence on current implanting practice 
for the population of County Durham and Darlington, assess the local pacemaker 
programming strategies employed and measure their effectiveness in terms of 
ventricular pacing avoidance and incidence of atrial fibrillation. 
 
8.2. Development of Research Questions 
Analysis of the literature review has led to the development of the following  
questions: 
1. What is the pacemaker implanting practice for patients in County Durham and 
Darlington with a primary implant indication of sick sinus syndrome?  
2. What, if any, algorithms are employed in these patients in an effort to reduce 
the amount of right ventricular pacing? 
3. What is the overall percentage of right ventricular pacing achieved by device 
choice and programming strategy? 
4. What is the overall percentage of time the patient has spent in atrial 
fibrillation, and is there any correlation to the RV pacing percentage or 
algorithm employed? 
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Research Question  Research Actions (question/ hypothesis) 
 
What is the implanting practice 
for patients 
in County Durham and Darlington 
with SSS? 
CDDFT is a single Trust with two cardiac 
device implanting centres. Review the patient 
demographics in terms of age/sex profile, 
implant rates, review device prescription. 
Validate the appropriateness of pacemaker 
prescriptions for patients with SSS 
What, if any, algorithms are 
employed in the pacemakers in an 
effort to reduce the amount of 
right ventricular pacing? 
Assess implanting and programming practice 
in light of evidence of deleterious effects of 
right ventricular pacing.   
What is the overall percentage of 
right ventricular pacing achieved 
by device choice and 
programming strategy? 
Explore the significance of difference between 
the ventricular pace avoidance algorithms. 
Identify which, if any, is most effective in 
reducing the amount of right ventricular 
pacing 
What is the overall percentage of 
time the patient has spent in atrial 
fibrillation and is there a 
correlation to RV and the use of 
algorithms 
Describe the percentage of AF and its 
distribution, evaluate any correlation with the 
degree of RVP. 
 
 
Table 8.2.1 –Relevance of Research Questions to Literature Review 
 
The purpose of the research thesis is to assess the “cardiac device algorithms for 
optimal outcomes in patients with sick sinus syndrome”. 
 
8.3. Development of the Methodology  
The research questions inform the research methodology: each research question has 
been considered in more detail to establish and justify appropriate methodology. 
I. What is the pacemaker implanting practice for patients in County Durham 
and Darlington with an aetiology of sick sinus syndrome?  
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The literature review and  the ACC/AHA/HRS Guidelines for Device Based Therapy: 
Executive Summary, details the national and international standards for cardiac 
pacemaker prescription in patients with sick sinus syndrome, it states “in the 
management of sick sinus syndrome in patients in whom, after full evaluation, there is 
no evidence of impaired atrioventricular conduction; in this situation, single-chamber 
atrial pacing is appropriate”. 
National implantable cardiac devices audit – Clinical Audit of Cardiac Device 
Implantation, has consistently shown the national tendency to implant dual chamber 
synchronous pacemakers (DDD) for patients with sick sinus syndrome. 
This audit shows that CDDFT implanting practice does mirror the national picture, 
with less than 1% AAI implants and 68% and 80% DDD respectively for the two 
implanting sites (Darlington Memorial and University Hospital of North Durham)  
within County Durham and Darlington NHS Foundation Trust (Cunningham 2009). 
The remainder of implants are single chamber ventricular based pacemakers VVI, 
presumably for the treatment of chronic atrial fibrillation with bradycardia. These 
data, however, do not give information on the modes implanted specifically for sick 
sinus syndrome and their capability to programme advanced algorithms that can 
reduce right ventricular pacing. 
CDDFT commenced pacemaker implantation in 2006, prior to this patients were 
referred to either James Cook University Hospital in Middlesbrough or Freeman 
Hospital in Newcastle for pacemaker implantation. 
The project looked at pacemaker data from the start of the implant services, when 
decisions on device prescription and programmable options were within the control of 
CDDFT. 
The more recent device algorithms offering an atrial paced mode with a back-up of 
synchronous dual chamber pacing were first launched in 2003 (ELA –Symphony™). 
Following a takeover by the Sorin Group, the second generation devices (SafeR™) 
were launched in 2005. Medtronic followed on shortly after with the release of 
EnRhythm and Adapta devices offering managed ventricular pacing MVP™ in 2006. 
Prior to this time the extension of the atrioventricular delay was the only method of 
allowing for normal ventricular conduction and activation. This remains the method 
of facilitating normal ventricular intrinsic conduction in the other manufacturers of 
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pacemakers and also features in other models of both Medtronic and Sorin group 
devices.  
The project, therefore, considered a 5 year period from when CDDFT commenced its 
own implanting service and when alternatives to AVD extension were available. Data 
were gathered up to a 5 year period post implantation to evaluate any degree of 
progression in terms of development of AV block or the long term effects on RV 
pacing and the development of atrial fibrillation. 
The project required data to be identified and logged based on certain criteria on all 
patients who received their implant and/or follow-up at CDDFT: 
Inclusion criteria – all patients who have permanent pacemaker implanted for primary 
indication of sick sinus syndrome. To include generator changes due to battery 
depletion. 
Exclusion criterion 1 – patients with primary implant indication of anything other than 
sick sinus syndrome. 
Exclusion criterion 2 – patients implanted at other pacemaker centres prior to CDDFT 
implanting service in 2006. These patients were outside of CDDFT implanting 
decisions and some pre-date the availability of devices with RV pace avoidance 
specific algorithms. 
Exclusion criterion 3 – patients programmed to VVI due to onset of chronic AF soon 
after implant or failure to implant an atrial lead. 
Exclusion criterion 4 – patients who had a mixed pathology of sick sinus syndrome 
and chronic AV block. 
Data Requirement 
- Age and sex profile, to compare any statistically significant difference in the age/sex 
characteristics of CDDFT pacemaker patients compared to national data.  
- The make and model of device to assess implanting practice in relation to sick sinus 
syndrome and availability of algorithms. (Some of the older devices do not have the 
programmable technologies and this information was verified by the make and 
model).  
- The programmed mode gives information on the mode selection against the 
international/national guidelines. 
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- An analysis of patients implanted for primary indication of SSS who went on to 
develop AV block or chronic atrial fibrillation, and relate this to published data 
(showing a <1% incidence of AVB per year). 
 
II. What, if any, algorithms are employed in the pacemakers in an effort to 
reduce the amount of right ventricular pacing? 
Data were gathered on the programmed algorithms employed by the two implanting 
sites in an effort to reduce the amount of RV pacing. This included an atrioventricular 
delay (AVD) programmed longer than physiologically normal (normal atrial to 
ventricular interval is less than 200 ms) or an extension/search algorithm which 
automatically extends the AVD to allow for intrinsic conduction, or a specific mode 
change that will operate in AAI mode with the ability to change to DDD in the 
presence of AVB (see algorithm explanation Section 7.2). 
There is a differentiation between the atrial paced and atrial sensed atrioventricular 
delays. This is due to detection of intrinsic atrial depolarisation occurring 20-60ms 
after the onset of the P wave in an electrical cycle, however the detection of an 
artificial paced event via the pacing spike is immediate. For this reason pacemaker 
programming usually had a 20-60ms offset between sensed and paced AV delays 
(Ellenbogen and Wood 2010). The degree of AVD extension was documented, 
together with any automated AVD extension algorithm. 
The presence of a specific and specialised mode switching algorithm for ventricular 
pace avoidance was documented (either MVP ™ by Medtronic or SafeR™ by Sorin). 
Inclusion criteria – all patients already selected with primary indication of SSS.  
Exclusion criteria – no further exclusions sought a priori. 
Data required – details of paced and sensed AV delays, and specific pace avoidance 
algorithms if any. This provided information on what additional features had been 
employed, if any, to reduce un-necessary ventricular pacing. 
 
III. What is the overall percentage of right ventricular pacing achieved by device 
choice and programming strategy? 
The literature review has suggested that RV apical pacing results in an increased risk 
of hospitalisation due to heart failure, especially in patients with known cardiac 
dysfunction and increased burden of atrial fibrillation. This has resulted in 
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technological developments of pacing strategies to avoid un-necessary ventricular 
pacing. These technologies have predominantly been incorporated into devices that 
extend AV delays or have specific algorithms that operate in AAI with the potential to 
switch to DDD in the presence of atrio-ventricular block. 
Inclusion criteria – all patients already included with primary indication of SSS. 
Exclusion criteria – no further exclusions expected. 
Data required – the percentage of RV pacing documented and averaged per year up to 
a 5 year period depending on the implant date. The percentage of atrial pacing was 
also assessed as this has a potential impact on ventricular pace burden with increased 
atrial sensor driven rate. This aspect of the data was not, however, analysed as there 
was no evidence in the literature on the influence of atrial pacing on the percentage of 
ventricular pacing. 
 
IV. What is the overall percentage of time the patient has spent in atrial 
fibrillation? 
Many of the large randomised clinical trials reviewed in Chapter 6 detailed the higher 
incidence of atrial fibrillation in the pacemaker population, specifically those with a 
high percentage of right ventricular apical pacing. Atrial fibrillation is associated with 
increased hospitalisation (See Fig: 6.2.1), reduction in cardiac output and cardiac 
performance due to the lack of atrial transport, asynchronous cardiac activation and 
increased risk of stroke. 
Inclusion criteria - all patients already included with primary indication of SSS. 
Exclusion criteria – no further exclusions sought a priori. 
Data required – the percentage of atrial fibrillation documented and averaged per year 
up to a 5 year period depending on the implant date. 
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8.4. Research Methodology 
 
 
 
 
Total number 
of patients 
with primary 
indication of 
SSS= 501 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8.4 Data processing schema 
DATA SOURCE  
Total number of patient files assessed = 1669 
All pacemaker patients under active follow-up with a 
primary pacemaker indication of SSS at all sites in 
CDDFT (BAH, DMH and UHND) had their device data 
files reviewed. This data is held in hard copy format on 
each site. (see Section 8.5). 
 
CORE DATA 
Data relevant to research question for evaluation and 
processing. Patients with SSS and their age/sex 
demographics, data on device modes/ algorithms utilised 
and the efficacy of these devices/algorithms in terms of 
RVP and AF burdens. Total number = 349 
STATISTICAL ANALYSIS 
349 patient records for analysis 
Exclusion Criteria: 
Development of AVB or 
chronic AF. Total excluded 
=63 (these 63 were further 
analysed in Section 9.1.3) 
Further exclusion if implant 
pre-2006 = 86 
Further exclusions if single 
atrial paced/sensed devices 
used (AAI)=3 
Additional data: 
AV extension and % 
Atrium  paced. 
 
RESULTS 
DATA SETS 
Data collected included the patients age at 
the time of review, the patients sex, when 
the device was implanted and where the 
patient receives their follow-up 
(BAH,DMH, or UHND). Data on device 
was also collected –manufacturer, model 
and mode of operation. The programming 
strategy employed was recorded in terms of 
AV delay strategy. Finally the amount of 
RVP per year and the amount of AF per 
year described as an annual percentage. 
Study period – 2006-11 
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8.5. Data Source and Management 
This was a retrospective analysis of existing patient data. 
All required data was gathered from patient pacemaker implantation and follow-up 
files which are held in secure cabinets in the Cardiac and Pulmonary Investigation 
Units at the hospital site where the patient receives their regular pacemaker follow-up 
– BAH, DMH or UHND. These files contain all the relevant implant details together 
with a clinical record of each clinic visit since the original implant. 
Each data field was populated on the Excel spread sheet (see Table 8.5.1), and stored 
to an encrypted mobile media and processed using CDDFT computers at each of the 
sites. Compliance with CDDFT information governance requirements in terms of 
maintenance of patient data confidentiality was ensured throughout the data gathering, 
processing and analysis. 
In order to analyse the SSS population and their response to device mode and 
programming strategy, they were assessed over a period of time. The decision on type 
or mode of device is made at the time of original implant, generally final 
programming strategy is decided at their post implant check (at CDDFT this at 1-2 
months post implant), and reviewed at 6 months. Patients are then followed up 
annually to monitor pacing status, pacemaker lead integrity and battery drain, further 
programming and device alterations may be undertaken depending on patient and 
device status at each clinic follow-up.  
It was estimated that there would be 1700 active patient data files from activity 
profiles (held on hospital clinic management system), with approximately 30% of 
implants for a primary indication of SSS suggested in the regional and national 
implant data (Section 4.3). There was an expected 5-10% exclusion rate due to 
chronic AF, forced ventricular pacing due to chronic AVB and lead displacement 
resulting in single chamber pacing (4% AVB rate suggested in DANPACE trial).  
Data was collected over a 5 year period to evaluate any change in pacing outcomes 
overtime due to the development of AVB or AF, a common arrhythmia especially in 
the aging population.(Wyndham 2000), however evidence from the literature review 
suggests that it is more common in the presence of patients with RVP. (Lamas, Lee et 
al 2000) 
The data was stored in a numerical form onto an Excel spread sheet to aid statistical 
analysis using Statistical Packages for the Social Sciences (SPSS 19) software. 
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Table 8.5.1 Examples of dataset Excel spread sheet, year 1 only shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID Site Sex Age Year of ImplantDevice model Mode prog AVD Pace AVD SenseAlgorithm Yr1% RV PaceYr1 % A PacedYr1 % AF
Example
B001 BAH M 76 2009 Sensia DR DDDR 250 220 AV Search 25 76 5
D002 DMH F 83 2011 Ensura DR AAIR<=>DR MVP 9 90 0
U003 UHND F 73 2007 Altrua DR DDDR 220 200 AVD long 30 55 0
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Chapter 9 – Data Analysis and Results 
The previous methodology section dealt with the formulation of the research 
questions, this section covers the associated methods of analysis using the core data 
set as illustrated in Section 8.4. 
The demographic data and implanting practices of the implant and follow-up centres 
in CDDFT is useful in assessing any deviance from recommendations and ensuring 
that outcomes, against the key question of cardiac device algorithms for optimal 
outcomes in patients with sick sinus syndrome, can be applied more widely if 
appropriate.  
 
The analysis now addresses the following key research questions: 
i. What is the most effective programmable algorithm or programming 
strategy to avoid ventricular pacing in patients with pure SSS? 
ii. Is there a correlation between the percentage of RVP and programming 
strategies and the burden of atrial fibrillation? 
Preliminary analysis of the data in relation to the study population was undertaken to 
identify any unexpected features of each variable in terms of their distribution.  
In the North of England Cardiovascular Network population 11% were over the age of 
70 years of age, and this population received 76% of the pacemakers. Furthermore 
there is a dominance of males receiving pacemakers over females.(Cunningham 2009) 
Analysis of the core data gave the age and sex distribution described in Section 9.4, 
this data was derived using descriptive statistics from IBM SPSS version 19 and 
reference book (Gray and Kinnear 2012) 
 
9.1. Core Data Set 
(As described by diagram in Section 8.4) 
All patients currently under active follow-up at any of the hospital sites within County 
Durham and Darlington: 
Bishop Auckland Hospital: 435 
Darlington Memorial Hospital: 550 
University Hospital of North Durham: 684 
Total number of patients reviewed: 1669 
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9.1.1. Exclusion of Pacemaker Indications other than SSS 
Of the total pacemaker patients undergoing active follow-up at any of the hospital 
sites, the total number of implants for a primary pacemaker indication of sick sinus 
syndrome: 
Bishop Auckland Hospital (BAH): 119 (29%) 
Darlington Memorial Hospital (DMH): 172 (31%) 
University Hospital of North Durham (UHND): 210 (31%) 
Total number of patients with SSS - 501 
Percentage of patients with primary indication of sick sinus syndrome at implant = 
30.3% 
 
9.1.2. Exclusion Due to Development of AVB or AF 
It is recognised that some patients with primary implant indication of SSS go on to 
develop chronic atrial fibrillation and or chronic atrioventricular block. It is difficult 
to surmise whether this is compounded by permanent pacing or if this is due to the 
original implant rationale being of a mixed pathology. There is a type of SSS 
(brady/tachy) that is characterised by the presence of atrial tachy-arrhythmias and 
sinus arrest: as such these patients display paroxysms of atrial tachy-arrhythmias 
which may develop into chronic or sustained atrial tachy-arrhythmias such as atrial 
fibrillation. Furthermore patients with SSS as their primary indication for pacemaker 
implantation may have more advanced disease of the conduction system involving the 
conduction down to the ventricles, thus developing atrioventricular block in addition 
to the primary pathology of SSS. A mixed pathology is not by any means uncommon. 
Although data have been collected and analysed on these patients in terms of the time 
from implant to onset of sustained atrial fibrillation or atrioventricular block, they 
were excluded from the dataset if they had developed these conduction disturbances 
chronically within their first year of follow-up, with an exclusion rationale of original 
mixed pathology.  
Patients were excluded due to development of AVB and/or AF, development of these 
abnormalities requires the AVD to be programmed to a more a physiologically normal 
delay (<200ms) and in the presence of chronic AF, single chamber ventricular paced 
and sensed (VVI) is generally indicated. 
 
  69 
 
Exclusion No. Patients Percent 
Valid AV Block 26 41.3 
A.F. 36 57.1 
Both 1 1.6 
Total 63 100.0 
Table 9.1.2 Exclusions due to AV block and/or atrial fibrillation 
 
The above data describes patients implanted and followed-up in CDDFT who were 
excluded from the study due to the early onset of chronic atrial fibrillation or 
atrioventricular block. The occurrence of chronic atrial fibrillation dominates at 57%, 
whilst the development of atrioventricular block, as determined by no R wave 
following either sensed or paced atrial event at maximum programmable 
atrioventricular delay (first degree atrioventricular block), or chronic underlying 
second or third degree atrioventricular block, was evident in 41% of patients. 
This gives an incidence of AVB development of 5% overall, compares quite closely 
to the 4% AVB development noted in the DANPACE study (DANPACE 2009).  
7% incidence of AF noted in the SSS study cohort. 
 
9.1.3. Time from Implant to Exclusion due to AVB or AF 
Further analysis was undertaken to establish when the development of atrioventricular 
block or atrial fibrillation occurred in patients whose dominant implant rationale was 
sick sinus syndrome. This analysis took information from the immediate post implant 
pacemaker function tests and cardiac rhythm assessment, this occurs in the routine 
pacemaker checks scheduled at 1 month, 6 months and 1 year. The rhythm 
disturbance was confirmed as chronic if it was maintained beyond 6 months from 
onset. 
Occurrence of Patients with Atrial Fibrillation and/or Atrio-Ventricular Block  
 
Time since implant AVB AF Both 
1 month F/U 15 22 1 
6 month F/U 7 0 0 
1 year F/U 14 4 0 
 
   
    
    
Note: Both=1 compromised AVB at 1 month and AF at 1 year of follow-up.  
   
Table 9.1.3 Time from Implant to development of AVB and/or AF 
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This data indicates that AF or AVB was observed and noted from the first month of 
implant in the largest number of patients: this suggests the existence of these 
conduction disturbances in addition to sick sinus syndrome at the time of implant. 
These data also highlights existing evidence that atrial tachy-arrhythmias are often a 
feature of sick sinus syndrome and that often disease of one part of the conduction 
system may affect other parts of the conduction pathway beyond the sinus node. 
 
9.1.4. Total Number of Patients with Pure SSS in Study 
Total number of patients with pure sick sinus syndrome as defined at 1 year of 
original implant: 
Bishop Auckland Hospital: 113 
Darlington Memorial Hospital: 143 
University Hospital of North Durham: 182 
    Total: 438 
 
9.1.5. Exclusions of Implants outside of CDDFT 
Patients whose original implant and programming decisions were made by other 
pacemaker services were removed from the dataset; this essentially excluded patients 
repatriated from other hospitals prior to 2006 when CDDFT services commenced. 
 The purpose of this research is to review CDDFT implanting and programming 
practices in order to appraise decisions in relation to mode and algorithm in the 
reduction of right ventricular pacing and development of atrial fibrillation. The device 
choice and programming strategy of other implanting centres may influence the 
patient longer term outcomes. Much of the research evidence from the larger 
randomised clinical trials (MOST, CTOP, DAVID) was undertaken, circa 2005. The 
broad availability of specific devices and algorithms to facilitate reduced RV pacing 
has been from 2003 -2005 - the review of implants from 2006 will allow for greater 
inclusion of these specific features. 
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9.1.6. Final Core Study Data  
This gave a final data source sampling size of: 
Bishop Auckland Hospital: 78 
Darlington Memorial Hospital: 121 
University Hospital of North Durham: 153 
Total sample size to evaluate cardiac device algorithms for optimal outcomes in 
patients with SSS was: 352 
 
Of these patients, 3 were implanted with single chamber atrial paced and sensed 
devices (AAI), for which there is no ventricular pace functionality. Although an 
appropriate mode for sick sinus syndrome, these devices have no necessity for 
ventricular pace avoidance and cannot offer information on the burden of AF. 
 
The exclusion process gave a final data size of 349 patients. 
It is important to note that this final data size only applies to patients within 1 year of 
implant, at each year thereafter the number decreases as the time from implant 
extends: 
Year 1 = 349 (yrs 2010 -2011) 
Year 2 = 285 (yrs 2009 – 2010) 
Year 3 = 190 (yrs 2008 -2009) 
Year 4 = 116 (yrs 2007 – 2008) 
Year 5 = 59  (yrs 2006-2007) 
The research was conducted on these 349 patients to develop conclusions against the 
research questions detailed in Chapter 8, understanding that these 349 patients would 
not all be present in the analysis in the subsequent years. 
 
Note: All patients implanted at either UHND or DMH for a primary indication of sick 
sinus syndrome were implanted with an atrial based system as recommended in NICE 
guidance. (National Institute for Clinical Excellence 2005) 
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 9.2. Null Hypothesis 
It is these 349 patients that were analysed in order to test the null hypothesis – “there 
is no difference in the degree of right ventricular pacing or the incidence of atrial 
fibrillation between the investigated pacemaker models and programming strategies in 
patients with sick sinus syndrome”. 
 
9.3 Sex and Age Distribution of the Study Population  
 No. Patients Percent 
Valid Male 164 47.0 
Female 185 53.0 
Total 349 100.0 
Table 9.3.1 – Sex distribution of study dataset 
 
The data shows that, unlike the regional implanting data from CCAD, there is a higher 
percentage of female pacemaker patients in the study dataset. The dataset relates only 
to patients with SSS and is subject to all the exclusions detailed in Section 9.1. This 
may not be representative of the whole population of pacemaker patients currently 
under active follow-up in CDDFT (1669 patients). 
Further analysis of the sex distribution was undertaken to see if there was any 
significant difference in the sex distribution to the follow-up hospital site. 
 
Table 9.3.2 Sex distribution of study population to hospital site – percentage in brackets. 
The data in Table 9.3.2 shows that the sex distribution is equal at Darlington 
Memorial Hospital, but a slightly higher female study population at both Bishop 
Auckland Hospital and University Hospital of North Durham. 
 
Age Distribution of the Study Population: 
Pacemakers are often regarded as a procedure occurring in the elderly population, and 
this generally held belief is supported by the national and regional data.  
 
 
Hospital Site 
Sex 
Total Male Female 
Site DMH 60 (36.6%) 60 (32.4%) 120 
BAH 32 (19.5%) 44 (23.8%) 76 
UHND 72 (43.9%) 81 (43.8%) 153 
Total 164 (100%) 185 (100%) 349 
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Most pacemakers are implanted due to diseases of the conduction system, which is 
predominantly a disease of the elderly. (Cunningham 2009)  
Case Summaries 
Age (in years) 
N Mean Median 
Std. 
Deviation Minimum Maximum 
Std. Error 
of Mean 
349 77.2 79.00 10.5 26 99 0.561 
Table. 9.3.3 Age range of the study population 
 
The mean age of 77 years of age is comparable with the national data (mean age of 76 
years – CCAD 2009) for all cause pacemakers. 
The range is broad at 26 to 99 years of age but a review of the age distribution below 
shows age ranges for the majority of the study population. This is also displayed for 
follow-up site to identify any differences in distribution to follow-up site. 
Fig 9.3.1 Graphical representation of age distribution and hospital site of study population. 
 
The distribution is negatively skewed towards the higher age ranges with the greater 
density between 70 and 90 years of age. The distribution is similar across the follow-
up sites. 
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Fig 9.3.2 Graphical representation of age and sex distribution of study population. 
The graph in 9.3.2 shows the age range for each sex, showing females dominating 
over males in the higher age ranges. This trend may relate to the higher numbers of 
females than males in the study and may also reflect the general historical trend of 
female life expectancy exceeding that of males, although this gap is closing. (Office 
of National Statistics 2012) 
9.4. Cardiac Device Distribution for Implanting Centre and Follow-up Site 
As previously described, pacemaker implantation occurs at either two sites in County 
Durham and Darlington: there is an implanting centre at Darlington Memorial 
Hospital and another at University Hospital of North Durham. 
There are a number of cardiac device makes and models available on the international 
market. Table 9.4.1 details of the makes of devices implanted in the study population 
for the treatment of SSS. 
There were 5 manufacturers of pacemakers within the core dataset. Within each 
manufacturer there was a number of differing pacemaker models, reflecting 
progressive technological processes, such as innovations of electronics and micro-
technologies, as well as emerging research data, improving these devices. 
Implantable cardiac devices represent a highly competitive market, and as such cost 
cannot be excluded as an influence on the device prescription decision making. 
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The Table 9.4.1 describes the models of devices in the core dataset in relation to the 
manufacturer. 
Medtronic provides the largest number of devices under a variety of different models 
for CDDFT, with Boston Scientific having the second largest share followed by Sorin 
Group and finally St Jude Medical.  
Section 9.5 describes the various algorithms available and their operation and shows 
that Medtronic and Sorin Group are the only manufacturers of devices with minimal 
ventricular pacing algorithms (see Section 7.5). 
Table. 9.4.1  Device Distribution -Table showing the distribution of manufacturers of the devices 
implanted in the study population 
Device model * Manufacturer Crosstabulation 
Count 
 
Manufacturer 
Total Medtronic 
St Jude 
Medical 
Boston 
Scientific Sorin Group 
Vitatron 
(Medtronic) 
Device model Adapta DR 20 0 0 0 0 20 
Altrua DR 0 0 69 0 0 69 
Enpulse DR 1 0 0 0 0 1 
Ensura DR 17 0 0 0 0 17 
Esprit DR 0 0 0 1 0 1 
Identity D 0 1 0 0 0 1 
Identity DR 0 37 0 0 0 37 
Insignia DR 0 0 20 0 0 20 
Integrity DR 0 1 0 0 0 1 
Kappa DR 6 0 0 0 0 6 
Reply SafeR 0 0 0 49 0 49 
Selection DR 0 0 0 0 1 1 
Sensia D 1 0 0 0 0 1 
Sensia DR 75 1 0 0 0 76 
Sigma D 1 0 0 0 0 1 
Symphony 0 0 0 14 0 14 
T70DR 0 0 0 0 19 19 
Verity DR 0 4 0 0 0 4 
Versa DR 3 0 0 0 0 3 
Victory DR 0 5 0 0 0 5 
Zephyr DR 0 3 0 0 0 3 
Total 124 52 89 64 20 349 
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Medtronic has the largest market share of the pacemaker implants at 124 giving a 
market share of 35.5%, with Boston Scientific having 25.5%, Sorin receive 18.3% of 
the market and 14.9% to St Jude Medical, the remaining 5.7% share of the market was 
with Vitatron (now owned by Medtronic). 
The model of device determines the availability of programmable algorithms and 
features of the device. 
The table below describes the device models by the site implanted. 
    Site 
Total (%) 
  Model DMH (%) UHND (%) 
 Adapta DR 5   (2.6) 15     (9.8) 20     (5.7) 
 Altrua DR 35 (17.9) 34   (22.2) 69      (20) 
 Enpulse DR  1   (0.5) 0 1     (0.3) 
 Ensura DR 16   (8.2) 1     (0.7) 17     (4.9) 
 Esprit DR   1   (0.5) 0 1     (0.3) 
 Identity D 1   (0.5) 0 1     (0.3) 
 Identity DR 28 (14.3) 9     (5.9) 37   (10.6) 
 Insignia DR 17   (8.7) 3        (2) 20     (5.7) 
 Integrity DR 0 1     (0.6) 1     (0.3) 
 Kappa DR 3    (1.5) 3        (2) 6     (1.7) 
 Reply SafeR 48  (24.5) 1     (0.6) 49      (14) 
 Selection DR 0 1     (0.6) 1    (0.3) 
 Sensia D 1    (0.5) 0 1    (0.3) 
 Sensia DR 14    (7.1) 62   (40.5) 76  (21.8) 
 Sigma D 1    (0.5) 0 1    (0.3) 
 SymphonyDR 14    (7.1) 0 14       (4) 
 T70DR 4       (2) 15     (9.8) 19    (5.4) 
 Verity DR 1    (0.5) 3        (2) 4    (1.1) 
 Versa DR 1    (0.5) 2     (1.3) 3    (0.9) 
 Victory DR 4       (2) 1     (0.6) 5    (1.4) 
 Zephyr DR 1    (0.5) 2     (1.3) 3    (0.9) 
Total 196 (100) 153  (100) 349  (100) 
Table 9.4.2 Table of device models implanted for each of the two implanting sites. 
There are differing implant decisions based on device model between the two sites.  
It is recognised that there are operator preferences that will have an influence over the 
device prescribed at implant: not just by the programmable algorithms but other 
factors such as size, shape, cost, product familiarity and product confidence.  
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The data suggest a greater use of devices with AAI DDD- minimal ventricular 
pacing, at DMH with 62 of the Sorin SafeR™ devices (Symphony and Reply SafeR) 
being implanted at DMH versus 1 at UHND. Of the Medtronic devices with available 
AAI DDD algorithm (Adapta and Ensura DR) 21 were implanted at DMH versus 
16 at UHND. This observation suggests a greater use of AAIDDD devices at DMH 
compared to UHND. The rationale behind these decisions has not been investigated as 
part of this project but should be considered further in the future in light of the 
outcomes from the data analysis. 
The most commonly used device was the Medtronic Sensia DR at 76 devices or 
21.7% of the total implants. Implantation was predominantly at the UHND site with 
62 devices versus 14 at DMH. This device has an AV search algorithm available.  
The second most implanted device was the Boston Altrua DR with total of 69 devices, 
evenly split between sites of 35 at DMH and 34 at UHND. The Altrua DR also has an 
AV search algorithm available for programming. 
As already described, there are national and international standards on device 
prescription in terms of mode but no such guidelines or recommendations in terms of 
programmable algorithms such as minimal ventricular pacing, mode switch, etc. 
CCAD (now the National Institute for Clinical Outcomes Research) reviews 
performance on an annual basis with a mandatory requirement for all implant centres 
in the UK to report on implanting practice. Implanting sites are performance managed 
by Primary Care Trusts and Regional Cardio-vascular Networks against these 
standards. 
There is NICE (National Institute for Clinical Excellence 2005) guidance stating that 
the pacing mode for patients with SSS should be atrial based i.e. dual chamber 
pacemaker or atrial based pacemaker (DDD or AAI).  The dataset has not shown 
evidence of any inappropriate device model prescription from either of the implanting 
sites – see Chapter 4 Pacemaker prescription. 
It was also noted in the regional data from CCAD in 2009 and 2010 (Fig. 4.3.2 and 
Fig. 4.3.4) that DDDR comprise the largest proportion of devices implanted in the 
North of England (Cunningham 2010). Previously, Chapter 3 described how patients 
with sinus node dysfunction or SSS may also exhibit a fixed heart rate when 
exercising – this is known as chronotropic incompetence. This abnormality manifests 
in fatigue and shortage of breath on exertion (Bennett 2006 pp:44-5). In these patients 
the addition of a sensor in the device that will increase the atrial pacing rate by 
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detecting movement and activity is indicated. This practice is further confirmed in 
Table 9.4.2 showing high volumes of devices coded DR or SafeR. 
The recognised additional coding for these types of devices is ® as stated in the 
pacemaker, defibrillator and lead codes (Bernstein 2000). 
 
9.4.1. Distribution of Device Models by Site of Follow-up        
Programming decisions are made at the follow-up visits. The table below shows the 
distribution of the implanted pacemaker models to the follow-up site. 
 
Device model * Site Crosstabulation 
Count 
Device model 
Follow-up Site 
Total DMH BAH UHND 
 Adapta DR 4 1 15 20 
Altrua DR 21 14 34 69 
Enpulse DR 1 0 0 1 
Ensura DR 12 4 1 17 
Esprit DR 1 0 0 1 
Identity D 0 1 0 1 
Identity DR 18 10 9 37 
Insignia DR 10 7 3 20 
Integrity DR 0 0 1 1 
Kappa DR 1 2 3 6 
Reply SafeR 28 20 1 49 
Selection DR 0 0 1 1 
Sensia D 1 0 0 1 
Sensia DR 7 7 62 76 
Sigma D 1 0 0 1 
Symphony DR 8 6 0 14 
T70DR 3 1 15 19 
Verity DR 0 1 3 4 
Versa DR 1 0 2 3 
Victory DR 2 2 1 5 
Zephyr DR 1 0 2 3 
Total 120 76 153 349 
Table 9.4.3 showing the distribution of the implanted models to the follow-up sites. 
  79 
 
 
9.5. Programmed Device Mode and Algorithms 
The availability of algorithms to minimise the amount of right ventricular pacing are 
available in most of the devices within the core dataset. The decision on when and 
how to programme these algorithms is left to the discretion of the clinician or cardiac 
physiologist engaged in the follow-up of the device. 
The device features available, such as algorithms or features to reduce ventricular 
pacing, are dependent on the device make and model. 
The table below (9.5.1) shows the main programmable features and specific 
algorithms available for each of the models of pacemaker implanted in the study 
population, also included in the table is further detail on the degree of extension (ms) 
that can be added to the AV delay (see also Chapter 7), and the two main minimal 
ventricular pace algorithms (MVP™ and SafeR™). 
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Table: 9.5.1  Table describing the features and algorithms available in the devices used in the study 
that can reduce the need for ventricular pacing 
 
To use an example from above, the Sensia DR was the most popular device used, if a 
paced AVD of 200ms and sensed AVD of 170ms were programmed, plus search of 
150ms. The device would extend the AVD out to 350 ms after an atrial paced event to 
search for intrinsic conduction and extend AVD to 320 ms after a sensed atrial event. 
This delay will remain extended for a number of pre-programmed cycles before 
reverting to the programmed shorter AVD if no intrinsic conduction is established. 
Device 
Model 
Manufacturer Paced AV 
Delay (ms) 
Sensed AV 
Delay (ms) 
AV Search (ms) SafeR 
AAIR-
DR 
MVP 
AAIR-
DR 
 
Adapta DR 
 
Medtronic 
30 – 350 30 – 350 Yes( +10 – 25) No Yes  
 
Altrua DR 
 
Boston  
10 – 300 10 - 100 less 
than PAV 
Yes (+10-100%) No No 
 
Enpulse DR 
 
Medtronic 
30 – 350 30 – 350 Yes (+10 – 250) No No 
 
Ensura DR 
 
Medtronic 
30 – 350 30 – 350 No No Yes  
 
Esprit DR 
 
Sorin 
30 – 250 0 - 125 <PAV Yes (10 – 345) No No 
 
Identity D 
 
St Jude 
25 – 350 150 – 250 Yes (+120 -110) No No 
 
Identity DR 
 
St Jude 
25 – 350 150 – 250 Yes (+120 - 110) No No 
 
Insignia DR 
 
Boston  
20 – 300 10 - 100 <PAV Yes (10 - 100%) No No 
 
Integrity DR 
 
St Jude 
25 – 350 25 – 325 Yes (10 – 120) No No 
 
Kappa DR 
 
Medtronic 
30 – 350 30 – 350 Yes (+10 – 100) No No 
 
Reply SafeR 
 
Sorin 
30 – 250 0 - 125 <PAV No Yes No 
 
Selection DR 
 
Vitatron 
80 – 300 45 – 260 Yes (+60 – 120) No No 
 
Sensia D 
 
Medtronic 
30 – 350 30 - 350  Yes +10 - 250 No No 
 
Sensia DR 
 
Medtronic 
30 – 350 30 – 350 Yes +10 -250 No No 
 
Sigma D 
 
Medtronic 
30 – 350 30 – 350 No No No 
 
Symphony DR 
 
Sorin 
30 – 250 0 - 125 <PAV No Yes No 
 
T70DR 
 
Vitatron 
80 – 300 45 – 260 Yes +60 - 120 No No 
 
Verity DR 
 
St Jude 
25 – 350 25 – 325 Yes +10 - 120 No No 
 
Versa DR 
 
Medtronic 
30 – 350 30 – 350 Yes +10 - 250 No No 
 
Victory DR 
 
St Jude 
25 – 350 70 – 170 Yes +200 - -110 No No 
 
Zephyr DR 
 
St Jude 
25 – 350 70 – 170 Yes +200 - -110 No No 
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The device will search again after a period of time or number of cycles, again the 
period of time and number of cycles is individually programmable. 
9.6. Age and Sex Influences on the use of Devices and Algorithm 
In order to ensure that the use and efficacy of the differing device modes and 
algorithms were not influenced by other factors such as the age or sex of the patients, 
analysis of the algorithms and the age and sex characteristics was statistically 
assessed. 
Non-parametric tests using Kruskal-Wallis comparing each of the 5 programming 
strategies/algorithms with the sex distribution for the null hypothesis of “the 
categories defined by sex=male and females occur with probabilities of 0.5 and 0.5” 
The table below summarises the retention or rejection of this null hypothesis. 
 
Algorithm Retain Null 
Hypothesis 
Reject Null 
Hypothesis 
No Algorithm   ×  
AVD Long   ×  
AV Search   ×  
AV Search+Long   ×  
MVP   ×  
Table 9.6.1 Summary of hypothesis testing for significant differences in the sex distribution for each 
algorithm 
 
The analysis of sex distribution in each algorithm group suggested that the 
distribution was not significantly different between males and females for each 
algorithm group. 
 
Further descriptive statistics were used for the age distributions for algorithm 
categories and displayed as Box plots. 
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Fig 9.6.1 Box plots showing the distribution of age for each algorithm 
The median values are similar across the categories of algorithms but a wider 
distribution of age ranges is seen in MVP group, which is also the largest single group 
in year 1. There needs to be further testing to identify any statistically significant 
differences in the age ranges between the algorithm groups. 
 
The Kruskal-Wallis test was used to test the hypothesis that the age distribution was 
the same across all categories of algorithm. The summary below shows that the null 
hypothesis was retained.  
 
 
Table 9.6.2 Hypothesis testing summary of age distribution across the algorithms 
 
The analysis of the sex and age distributions between the algorithms in the study 
population was not statistically different, therefore further analysis of the effects of 
these algorithms on the amount of RV pacing and consequent effects on the degree of 
AF, was not likely to be skewed by influences of the patient’s age or sex. 
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9.7. Analysis of the Efficacy of Programmable Device Features in Reducing 
RV Pacing 
Chapter 5 described the potential effects of right ventricular apical pacing. The key 
question posed in this research is “what is the most effective programmable algorithm 
or programming strategy to avoid ventricular pacing in patients with pure sick sinus 
syndrome?” 
The annual amount of right ventricular pacing was collected for each follow-up year 
and described as a percentage of the overall pacing detected in the ventricle. 
The baseline for comparison was patients in which no specific programming was 
undertaken to reduce the amount of right ventricular pacing ‘no algorithm’. The total 
number of patients in the study for which no alterations to standard programming 
were made to reduce the likelihood of right ventricular pacing was 14. 
Chapter 7 described the available pacemaker algorithms with specific detail on the 
atrioventricular delay. There are effectively 5 programmable features although MVP 
and SafeR™ can be considered as the same algorithm, operating in effectively the 
same way but with slight differences in the AVB criteria. 
The table below shows the algorithms utilised at each of the follow-up centres. 
Site of Follow-up and Algorithm Utilised 
Count 
Hospital follow-up 
Site 
Algorithm 
Total    
(%) 
No 
Algorithm 
(%) 
AVD 
Long  
(%) 
AV 
Search 
(%) 
AVD 
long+search 
(%) 
MVP   
(%) 
SafeR 
(%) 
Site DMH 4 (28.6)   27 (48.2) 2  (2.4) 35   (36.5)  16 (43.2) 36 (57.1) 120 (34.4) 
BAH 3 (21.4)  15 (26.8)  6  (7.2) 21   (21.9) 5 (13.5) 26 (41.2) 76 (21.8) 
UHND   7 (50)  14 (25) 75 (90.4) 40   (41.6)  16 (43.3) 1   (1.7) 153 (43.8) 
Total    14  56  83    96  37  63  349 
Table: 9.7.1 Device algorithms employed by each follow-up centre (No algorithm=no specific 
changes made to nominal atrio-ventricular delay, AVD Long=atrio-ventricular delay 
programmed longer than physiological i.e. >200ms, AV Search=specific automatic algorithm 
that extends atrio-ventricular delay to a max programmed searching for intrinsic conduction, 
AVD long+search=longer starting atrio-ventricular delay with added search, 
MVP™=managed ventricular pacing is a specific Medtronic algorithm which operates only in 
the atrium but switches to both atrial and ventricular pacing if atrio-ventricular block occurs, 
SafeR™ =specific Sorin algorithm which operates only in the atrium but switches to both 
atrial and ventricular pacing if atrio-ventricular block occurs. 
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Fig 9.7.1 Bar chart representation of device algorithm distribution for each follow-up site 
DMH=Darlington Memorial Hospital, BAH=Bishop Auckland Hospital, 
UHND=University Hospital for North Durham 
 
This graph shows a dominance of AV search algorithm at UHND site with a fairly 
even split between AV long + search and MVP at BAH and DMH. This suggests a 
more proactive or aggressive approach to reducing RVA pacing at BAH and DMH. 
SafeR is the dominant MVP device at BAH/DMH with Medtronic MVP device 
preferred at UHND. 
It can be concluded that there is a lack of consistency in the use of algorithms between 
BAH/DMH and UHND – being generally similar between BAH and DMH. 
This can be explained by the same staff covering the clinics at BAH and DMH with 
different staff covering UHND. 
This finding underlines the need to identify an evidence based approach to 
programming devices in an effort to reduce the degree of RV pacing which can be 
consistently applied across the services in CDDFT. 
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9.8. Overall Distribution of Right Ventricular Pacing  
Data Distribution 
 
Fig 9.8.1 – Distribution curves for the percentage of right ventricular pacing in each year group. 
 
The following observations were made from the RV pacing % distribution curves: 
 Severely non-normal positively skewed distribution 
 Approximately 50% of the readings are tied values at zero 
 Non-parametric statistical methods of analysis would need to be undertaken 
 Analysis of variance would be inappropriate as the assumptions behind 
ANOVA would be violated. The residual errors would be highly systematic 
and not random. 
 
9.8.1. Mean RV Pacing (Percentage) Achieved by Algorithm 
A series of case summaries was used to look at the distribution of mean annual right 
ventricular pacing percentage for each algorithm and for each year from implant. 
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i. Year 1 % RV Pace 
 
 
 
ii. Year 2 % RV Pace 
 
 
iii. Year 3 % RV Pace 
 
 
 
 
 
 
 
 
 
 
Algorithm N Mean Median Minimum Maximum 
No algorithm 14 78.1 93.5 0 100 
Long AVD 56 27.4 9.0 0 100 
AV Search 83 21.7 4.0 0 100 
Long AVD+AV search 96 19.5 4.5 0 100 
MVP 36 2.9 .0 0 59 
SafeR 64 1.6 .0 0 38 
Total (n=) 349     
Algorithm N Mean Median Minimum Maximum 
No algorithm 11 59.0 91.00 0 100 
Long AVD 41 21.8 7.00 0 100 
AV Search 71 19.8 3.00 0 100 
Long AVD+AV search 84 17.3 5.00 0 100 
MVP 26 2.7 .00 0 23 
SafeR 52 3.1 .00 0 49 
Total (n=) 285     
Algorithm N Mean Median Minimum Maximum 
No algorithm 7 46.0 33.0 3 99 
Long AVD 31 20.0 5.0 0 98 
AV Search 61 22.1 4.0 0 100 
Long AVD+AV search 56 19.1 5.0 0 100 
MVP 15 2.4 .0 0 26 
SafeR 20 3.9 .0 0 50 
Total (n=) 190     
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iv. Year 4 % RV Pace 
Algorithm N Mean Median Minimum Maximum 
No Algorithm 6 42.50 28.50 7 100 
Long AV Delay 23 22.13 12.00 0 96 
AV Search 42 27.55 4.00 0 100 
Long AVD + Search 33 19.52 9.00 0 95 
MVP 6 2.00 .00 0 9 
SafeR 6 10.33 .50 0 58 
Total 116 22.75 6.00 0 100 
 
 
 
 
v. Year 5 % RV Pace 
 
Tables 9.8.1 (i-v) Yr1-Yr5, mean annual RV pace percentage for each programmed algorithm 
 
Observations from the Case Summaries 
 Year 1 has the largest sample size with the full 349 dataset included in the 
analysis, the most RV pacing was observed in the “no algorithm” data with 
mean of 78% with the least mean RV pacing noted in MVP and SafeR 
algorithms with 2.9% and 1.6% respectively. 
 The statistics are less robust due to the smaller core data size in years 4 and 5. 
 Given that MVP and SafeR algorithms effectively operate in the same way by 
functioning in the atrium with a back-up mode to pace the ventricle when 
Algorithm N Mean Median Minimum Maximum 
No Algorithm 4 29.25 15.50 0 86 
Long AV Delay 14 24.36 8.50 0 100 
AV Search 19 10.89 2.00 0 76 
Long AVD+Search 18 16.72 11.50 0 63 
MVP 4 20.00 .00 0 80 
Total 59 17.73 6.00 0 100 
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atrioventricular block exists and there is little difference in their efficacy in 
terms of percentage of RV pacing, further analysis was on the basis of these 
two devices operating using the same algorithm. They were jointly coded as 
MVP giving the following visual distribution when grouped into mean RV 
pacing percentage bandings. 
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9.8.2. Distribution of RV Pacing by Algorithm using Box Plots 
 
 
Fig. 9.8.2 – Graphs showing 
the percentage of RV pacing 
grouped into %age 
bandings. All showing 
dominance in the 0-
10% (with exception of 
no algorithm), with a 
less uniform 
distribution in years 3-5 
where there are more 
devices with AV 
algorithms compared to 
MVP devices 
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Fig 9.8.3 Box plots – non-parametric properties of the distribution of RV pacing for each year paced. 
 
The above Box plots describe the medians of the data for each algorithm denoted by 
the horizontal line in the shaded box (note median line n MVP at zero – see case 
summary reports in Tables 9.8.1). The data in the box is the middle 50% of the data 
with the upper and lower quartiles above and below the horizontal line of the shaded 
box. The top of the shaded box and the horizontal line of the vertical line, or whisker, 
shows the top 25% and the lower vertical line, or whisker, below the tinted box shows 
the bottom 25% values.(Field 2009 pp:101) 
There are a number of outliers (numbers next to small circles) in the data. 
 Years 1-3 show little variation in the median RV pacing between AVD long, AV 
Search and AVD long+search with greater differences between the control  (no 
algorithm)and all algorithms, and MVP and all algorithms. 
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Further analysis is required to explore statistical significance of the differences 
between the algorithms, especially between AVD long, AV search and AV long+ 
search. 
 
9.8.3. Statistical Significance in the Percentage of RV Pacing Between 
Algorithms. 
The RVP annual percentage data has a non-Normal distribution, non-parametric 
testing was used and as there was a number of independent groups (algorithms), 
Kruskal-Wallis test was used to identify statistical differences between the algorithms. 
Due to the non-Normal distribution of the data, Krsukal-Wallis works on the basis of 
ranked data. Ordering the data from the lowest score to the highest and ranking the 
data on the basis of that score; it is these ranks that are analysed. 
This type of statistic has a Chi-squared distribution with a value for the degrees of 
freedom being 1 less than the number of groups. 
The outputs below from the SPSS programme give a significance value which is 
p<0.05 and a confidence interval on this p value is also calculated. 
 
Ranks 
 Algorithm N Mean Rank 
Yr1% RV Pace No Algorithm 14 306 
AVD long 56 222 
AV Search 83 199 
AV search+long 95 191 
MVP 101 96 
Total 349  
 
Kruskal-Wallis Test Yr1 
 Yr1% RV Pace 
Chi-Square 110.748 
Df 4 
Asymp. Sig. <0.001 
Monte Carlo Sig. Sig. <0.001 
99% Confidence Interval Lower Bound <0.001 
Upper Bound <0.001 
 
Table: 9.8.2 Kruskal-Wallis test showing summary of ranked data for each algorithm and test for 
significance between the variables, Year 1. 
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The computations associated with this statistical analysis, using the Exact method, are 
often extremely large and the SPSS system generates, like other statistical packages, 
sample tables for easier computation without substantially affecting the p value. This 
has been checked by repeating the analysis with different starting seeds. 
This test shows that 1 or more of the programmed algorithms has a significant effect 
on the percentage of RV pacing in year 1 (p<0.05). Further post hoc testing (Mann-
Whitney), which was adjusted for multiple testing thereafter, identified the statistical 
significance at individual algorithm level. 
Further testing was performed for years 2-5 to see if the statistical significance 
remains the comparable over time, including post hoc tests. 
 
 
a)  
Kruskal-Wallis Year 2 
 Yr2 % RV Pace 
Chi-Square 62.871 
Df 4 
Asymp. Sig. <0.001 
Monte Carlo Sig. Sig. <0.001 
99% Confidence Interval Lower Bound <0.001 
Upper Bound <0.001 
 
 
b)  
 
Kruskal-Wallis Year 3 
 Yr3 % RV Pace 
Chi-Square 38.065 
Df 4 
Asymp. Sig. <0.001 
Monte Carlo Sig. Sig. <0.001 
99% Confidence Interval Lower Bound <0.001 
Upper Bound <0.001 
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c)  
Kruskal-Wallis Year 4 
 Yr4 % RV Pace 
Chi-Square 13.150 
Df 4 
Asymp. Sig. 0.011 
Monte Carlo Sig. Sig. 0.008 
99% Confidence Interval Lower Bound 0.006 
Upper Bound 0.010 
 
 
 
 
d)  
Kruskal-Wallis Year 5 
 Yr5 % RV Pace 
Chi-Square 4.850 
Df 4 
Asymp. Sig. .303 
Monte Carlo Sig. Sig. .309 
99% Confidence Interval Lower Bound .297 
Upper Bound .321 
 
 
 
Table: 9.8.2 a,b,c,d.  Kruskal-Wallis tests for Years 2-5 testing significance of algorithms on RV 
pacing. 
 
These tables show that there is a statistically significant relationship between the 
programmed algorithm and the degree of right ventricular pacing (percentage per 
year) with significance of p=<0.01. This is evident in every subsequent year except 
year 5 where the trend is non-significant, probably reflecting the small sample size 
(n=59). 
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Table 9.8.3 Summary of Kruskal-Wallis tests for each year analysed looking for statistical significance 
against the null hypothesis of “ no significant difference in the degree of RV pacing between 
algorithms”. (Note SPSS output gives significance as .000 which approximates to p <0.001) 
 
The data analysis using Kruskal-Wallis test shows a significant difference between the 
pacing algorithms chosen and percentage of right ventricular pacing for each year 1-4. 
 
It can be deducted from the descriptive statistics in 9.8.1 and the case summary tables, 
that MVP and SafeR  were associated with the lowest mean percentage of RV pacing 
in years 1-4 with the data becoming less valid in year 5. 
The Kruskal-Wallis test shows statistical differences between all the algorithms in 
year 1-4, however there is a need for further analysis to demonstrate if there is 
statistical significance between each algorithm. 
This analysis required post hoc procedures on the Kruskal-Wallis test, to look at each 
algorithm against each of the other to look for statistical significance for each pairing. 
The post hoc procedure used is the Mann-Whitney test which compares two 
independent conditions (Field 2009 pp:540) and the p-value adjusted for multiple 
testing (p-value)/(n!/((n-1)!*2!) for n groups being compared. For 5 groups this would 
be 0.05/(5.4.3.2.1/(3.2.1*2.1))=0.005. 
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9.8.4. Post Hoc Testing of Combinations of Algorithms Pairs Testing for 
Statistical Significance  
The non-parametric testing suggested that there is a statistically significant 
relationship between algorithm and percentage of RV pacing, however it lacked any 
specificity. 
Post hoc testing (Mann-Whitney) was used to identify the relationships between each 
algorithm and for each year. 
As this involved more tests on the data, a decrease to the p value to 0.005 was used as 
the marker of statistical significance (see explanation above). 
Mann-Whitney paired comparisons were performed for each subsequent year and 
displayed, as a summary, in the matrix below.  
In years 1-3 there was statistically significant differences observed between “no 
algorithm” and all other algorithms and between MVP and all other algorithms. In 
year 4 there was a statistically significant difference between MVP and “no 
algorithm” and AVD long and in year 5 there was no statistical significant differences 
between any of the pairings. (P=<0.005) 
As with previous data analyses the data in years 4 and 5 have much smaller samples 
and data is likely to be less reliable. 
The following table (9.8.4) summarises which algorithms have the most statistically 
significant effect on the percentage of RV pacing. 
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Algorithm Yr 1 
 
No Algorithm AV Long AV Search AV search+long MVP 
No Algorithm          
AVD Long   ×  ×    
AV Search    ×    
AV search+long       
MVP      
Algorithm Yr2 No Algorithm AV Long AV Search AV search+long MVP 
No Algorithm  ×  ×  ×    
AVD Long   ×  ×    
AV Search    ×    
AV search+long       
MVP      
Algorithm Yr3 No Algorithm AV Long AV Search AV search+long MVP 
No Algorithm  ×  ×  ×    
AVD Long   ×  ×    
AV Search    ×    
AV search+long       
MVP      
Algorithm Yr4 No Algorithm AV Long AV Search AV search+long MVP 
No Algorithm  ×  ×  ×    
AVD Long   ×  ×    
AV Search    ×  ×  
AV search+long     ×  
MVP      
Algorithm Yr5 No Algorithm AV Long AV Search Av search+long MVP 
No Algorithm  ×  ×  ×  ×  
AVD Long   ×  ×  ×  
AV Search    ×  ×  
AV search+long     ×  
MVP      
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Table 9.8.4 a simplified summary of the statistical significant differences between pairs of algorithms 
showing the algorithms pairs for which there is statistical significance at a value of p= <0.005, Using 
Mann-Whitney post hoc testing. 
 
These data visually highlight the impact of MVP and confirm significantly lower rates 
of RV pacing in all years except for year 5, and when compared to AV search and AV 
search+long in year 4, p= <0.005 (equivalent to p=0.05). 
‘No algorithm’ shows statistical significance in its effect on RV pacing in year 1 only. 
 
9.9. Analysis of Time Spent in Atrial Fibrillation 
Many of the major trials detailed in Chapter 6 suggested that a potential complication 
of pacing is the development of atrial fibrillation (AF). The reported incidence of 
atrial fibrillation in the elderly population is 30-44%, whilst in the elderly pacemaker 
population it is 48% (Wyndham 2000) The key risk element in AF is 
thromboembolism and stroke. 
The final question posed by this thesis was to identify any correlation between the 
degree of RV pacing or algorithm and the overall burden of atrial fibrillation 
(percentage per year). 
The first analysis identifies the overall percentage of pacing for all of the patients for 
each of the years – again looking over a period of time to identify any progression 
with age. 
What cannot be concluded from this research is the likelihood of the study population 
developing AF, whether or not they had a pacemaker implanted 
Time Spent in AF   
Statistics 
 Yr1 % AF Yr2 % AF Yr3 % AF Yr4 % AF Yr5 % AF 
N Valid 348 285 190 115 57 
*Data not currently    
available 
1 64 159 234 292 
Mean 3.1 4.5 5.2 7.4 13.7 
Std. Error of Mean .636 .961 1.086 1.847 3.732 
Median .00 .00 .00 .00 .00 
Std. Deviation 11.872 16.222 14.964 19.807 28.178 
Minimum 0 0 0 0 0 
Maximum 100 100 93 100 100 
      
*No current data available due to time since implant. 
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Table 9.8.5 – Descriptive summary showing the mean atrial fibrillation burden per year for all devices, 
as a percentage. For example a mean of 3.1% represents the mean time spent on atrial fibrillation 
across the dataset. Patients with 100% ventricular pacing have not been excluded if not considered 
chronic at time of follow-up (would be programmed VVI once 100% AF for up to 1 year – see pg 68) 
 
It must be noted that the distributions are non-Normal as inferred by the magnitude of 
the standard deviation around the mean: on the basis of Normality, much of the 
observations would be negative which would be incorrect demonstrating the non-
normality of the data. 
 
Although the percentage of atrial fibrillations is generally low it incrementally 
increases with years from original implant – or patient age. Further testing was used to 
establish any correlation between the burden of atrial fibrillation and percentage of 
RV pacing and/or algorithm. 
In order to decide on the most appropriate method of statistical analysis the data 
distribution was evaluated. 
 
9.9.1. Distribution of Annual Percentage of Atrial Fibrillation 
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Fig 9.9.1 Yearly AF distribution for each year showing extremely non-Normal distribution. 
Given the non-Normal distribution of the data for atrial fibrillation, non-parametric 
statistical testing was used. The question requires a correlation between the algorithm 
used, the percentage of RV pacing and the overall burden of atrial fibrillation 
(percentage per year). 
Spearman’s rho statistical testing was deemed as the most appropriate method based 
on the non-parametric nature of the data. 
Spearman rho correlations were performed on RV pace percentage and AF in each of 
the years, the results are summarised below. 
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Yr1 AF%  
RV Pace% 0.003/1.000 Sig. (2 Tailed)/Correlation Coefficient 
Yr2 AF%  
RV Pace% 0.006/.162 Sig. (2 Tailed)/Correlation Coefficient 
Yr3 AF%  
RV Pace% <0.001/.308 Sig. (2 Tailed)/Correlation Coefficient 
Yr4 AF%  
RV Pace% 0.01/.236 Sig. (2 Tailed)/Correlation Coefficient 
Yr5 AF%  
RV Pace% 0.216/.167 Sig. (2 Tailed)/Correlation Coefficient 
 
Table 9.9.2 Spearman rho correlation between percentage of RV pacing and atrial fibrillation. Table 
details the p value/correlation co-efficient for each correlation 
 
This table shows that in all years except year 5, there is a correlation between the 
overall annual percentage of RV pacing and the overall annual percentage of AF, 
correlated at significance of p<0.05. 
In terms of atrial fibrillation, there is a direct correlation between the degree of RV 
pacing and the burden of AF as detailed in Section 9.7. As algorithm category indices 
are in no particular order they cannot be correlated with AF and therefore correlation 
analysis could not be undertaken. However it could be concluded that any algorithm 
that reduces RV pacing is likely reduce the amount of AF.  
It can therefore be concluded that there is a direct influence of the programmed 
algorithm on the overall percentage of RV pacing which in turn appears to affect the 
prevalence of AF. 
As with other aspects of the research analysis, the overall sample size and range 
across the differing algorithms is small and poorly distributed, this skews the analysis 
and makes year 5 less reliable in terms of generating robust conclusions. 
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Chapter 10 – Discussion 
10.1. Clinical Overview of Cardiac Pacing 
Bradyarrhythmias are commonly as a result of degeneration of the cardiac electrical 
conduction system. The heart has its own intrinsic electrical conduction system which 
stimulates the mechanical events of systole and diastole, although there are 
sympathetic and parasympathetic influences on heart rate, the cardiac conduction 
system is largely independent of overall neurological control. 
Cardiac muscle, like other muscles, has the ability to react to external artificial 
electrical stimulus thus producing an action potential resulting in contraction. These 
cardiac features have allowed for the development of small electrical generators to be 
implanted connected to electrical conductors (leads) sited in or on the heart muscle 
surface. These electrical pulse generators called pacemakers, support the intrinsic 
electrical conduction of the heart and hence maintain the mechanical events that will 
sustain life. 
The use of artificial cardiac pacing as the treatment of choice for chronic symptomatic 
bradycardias has been well established worldwide. Although there has been 
considerable technological advancement in terms of the size, longevity and 
programming sophistication of these devices, it cannot be ignored that the artificial 
replication of the cardiac conduction by these devices is not without its 
haemodynamic and physiological compromise and consequences. 
There are certainly cardiac conduction abnormalities for which ventricular pacing is 
unavoidable, such as atrioventricular block and chronic atrial fibrillation with 
bradycardia; there is however programming scope and device decisions that can be 
made to minimise the degree of RVP. 
 
10.2. Review of Implanting Practice- CDDFT 
There are clear guidelines on the use of devices for specific cardiac conduction 
abnormalities (Epstein, DiMarco et al. 2008), and reviewing CDDFT implanting data 
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against the local and national practice would suggest that there is compliance with 
appropriate device and mode prescription.  
In the pacemaker implant population, the national incidence of SSS was 27.5% in 
2010, with the incidence in the population of County Durham and Darlington at 
29.3%. 
The guidance recommends that patients with an indication of SSS should receive an 
atrial based pacing system for the treatment of this syndrome. In 2010 the UK rate of 
atrial based pacing systems for SSS was 84%. For the 2 implanting centres in CDDFT 
there was 91.9% atrial based pacing for SSS in UHND and 95.2% in DMH. 
This would suggest that the local pacemaker implanting practice for patients in 
County Durham and Darlington with an aetiology of SSS is in keeping with 
international guidelines and at rates higher than the national average.(Cunningham 
2010) 
In 2010, CDDFT implanted 0.6% AAIR devices in total with the majority of patient 
receiving DDDR devices for all aetiologies. Again these data indicate that the 
implanting practice for CDDFT is largely in-line with national and regional practice 
for SSS with a strong compliance against the use of systems that are solely atrial 
based: the almost exclusive preference was for the use of DDDR systems. 
 
10.2.1. Use of Device Modes in SSS (study population) 
Out of the 349 patients reviewed in year 1 of the study with an aetiology of SSS, only 
3 patients did not have a rate responsive pacemaker for rate regulation. 
100 (28.7%) devices had a minimal ventricular pacing algorithm programmes 
AAIDDD, 96 (27.5%) had a long AVD and AV search programmed, 83 (23.8%) 
had AV search only, 56 (16%) AVD long only and 14 (4%) patients had no algorithm 
programmed in an effort to reduce RV pacing. 
This would indicate that there is a proactive effort in the pacemaker clinics in CDDFT 
to use devices and algorithms in an attempt to reduce the need for unnecessary RV 
pacing in patients with SSS.  
10.3. Review of Efficacy of Pacing Strategies Utilised in CDDFT 
Chapter 9 compared all strategies employed in CDDFT cardiac device services in an 
effort to reduce ventricular pacing. It must be noted that in only 4% of patients(14 in 
year 1) there had been no active programming to reduce RV pacing, although these 
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devices did have the capability for AVD modification/extension, it was not 
programmed per se. It may be appropriate to review these 14 patient files to 
understand the rationale in these cases. 
 What is unclear from the national and regional reported data is whether CDDFT is 
unusual in its proactive approach to reducing unnecessary RVP or whether this is 
common practice regionally or indeed nationally. 
Given the volume of evidence supporting the potential for adverse effects of 
inappropriate RV pacing, there is no national guidance on post implant programming 
or benchmarking against this as a standard in cardiac device management. The 
nationally reported data only covers the immediate device prescription. 
 
Data analysis of the study dataset indicates an overwhelming reduction in RV pacing 
using the more recent MVP algorithms AAIDDD over any of the other strategies 
involving AVD programming. 
Years 1-3 showed <4% RV pacing burden with both minimal ventricular pacing 
algorithms, compared to an RV pacing burden of between 17% and 27% for all other 
programmed algorithms. Of the AVD algorithms AVD long + search being the most 
effective in years 1-3. By comparison, patients with no algorithm had an RV pacing 
percentage of 46-78% over years 1-3. 
 The data in years 4 and 5 are less reliable as the sample size reduces to 116 and 59 
respectively, with each algorithm disproportionately represented for reliable 
comparison. 
Given that MVP and “no algorithm” showing respectively the lowest and highest 
percentage of RVP, further statistical analysis of the data was undertaken to assess if 
there was any statistically significant difference between the 3 AV extension 
algorithms - AVD long, AV search and AVD long +search in their effect on the 
amount of RV pacing.  
It was concluded that there was no statistically significant difference between these 3 
algorithms in the effect on the overall percentage of RVP at a p value of <0.05. 
 
In terms of the effect of varying programming strategies on the burden of atrial 
fibrillation, testing was not able to reliably show any direct correlation between 
algorithm and the overall burden of atrial fibrillation. However, in keeping with the 
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research, there is a statistically significant correlation between the percentage of RV 
pacing and the burden of AF in years 1-4 (p=<0.05) 
10.4. Study Limitations 
This study was a non-randomised review of patients with existing devices, there are 
obvious opportunities for bias in terms of the original implant, the programming and 
the data selection. The conclusions should be considered against a background of 
these limitations. 
This study reviewed patients with SSS only; there is scope for reviewing the use of 
algorithms, such as MVP, in patients with intermittent AV block given the same 
potential for deleterious effects due to long term RV pacing especially if the AV block 
is not a chronic condition in many patients. 
The study sought to review RV pacing over a number of years from implant to see if 
efficacy of algorithms altered with time, this data became unreliable after year 3 due 
to small numbers and large variability between numbers in each of the algorithm 
groups.  
Given the analysis of the data of AVB/AF development from implant, suggesting that 
development of AVB or AF occurred within the first year from implant (Section 
9.1.3), the development of chronic AVB  or AF does not seem to develop in greater 
proportions in the SSS population than the normal elderly population. The value of 
the data collected beyond the first or second year added little value to the research 
overall. 
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Chapter 11 – Recommendations and Conclusions 
11.1. Recommendations for CDDFT 
The research sought to identify “cardiac device algorithms for optimal outcomes in 
patients with sick sinus syndrome” by posing the following key questions: 
I. What is the most effective programmable algorithm or programming strategy 
to avoid ventricular pacing in patients with pure sick sinus syndrome? 
II. Is there a correlation between these strategies and the burden of atrial 
fibrillation? 
The use of MVP algorithms that use the mode AAIDDD was associated with 
superior effectiveness in reducing the amount of RV pacing in patients with sick sinus 
syndrome. The efficacy of the other programmable algorithms, although effective at 
below 30%, were all less effective that MVP. There is no statistically significant 
difference in the efficacy between AVD long, AV search and AV search+long. 
In terms of atrial fibrillation, there is a direct correlation between the degree of RV 
pacing and the burden of AF. As algorithm category indices are in no particular order 
they cannot be correlated with AF and therefore correlation analysis could not be 
undertaken. However it could be concluded that any algorithm that reduces RV pacing 
is likely reduce the amount of AF.  
This research did not include a cost-based analysis, and it must be recognised that 
MVP devices are more expensive than standard dual chamber devices and as such any 
recommendations will be based purely on the clinical evidence. 
The recommendations from this research for CDDFT pacemaker implanting and 
follow-up service is to implant devices with available MVP algorithms in patients 
with sick sinus syndrome as this will reduce unnecessary ventricular pacing, with its 
potential deleterious effects on cardiac function, and reduce the burden of AF and its 
potential for thromboembolisms and stroke. 
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11.2. Conclusions 
This research project has identified the historical inconsistencies of implanting and 
programming practice in CDDFT. The long term effects of pacing, as the treatment of 
choice for bradyarrhythmias, has only relatively recently been fully evaluated and 
widely published. 
An integral part of this research project was evaluation of the literature and review of 
the clinical trials in relation to deleterious effects of RVP, this evidence must form an 
integral part of the decision making process when decisions are made on the 
implantation and programming practice. 
The national guidelines have been the mainstay of benchmarking and performance 
review in terms of appropriate devices for the indication for pacing, however this 
research project would suggest that the wider context of available programming 
strategies to ensure that the level of pacing delivered is clinically effective in terms of 
maintaining adequate conduction support but ensuring as normal an intrinsic 
conduction as possible. 
In the case of SSS, the evidence would support the use of MVP devices as being the 
most effective pacing strategy, with little evidence of adverse consequences.  
If we are to provide the best outcomes for pacemaker patients, then there needs to be a 
proactive attempt to reduce un-necessary RVP wherever possible, the evidence would 
also suggest that reducing the unnecessary pacing may also have an effect on reducing 
the incidence of atrial fibrillation. 
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